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Abstract
Nerve regeneration techniques have been studied in great depth in recent years. Peripheral nerve
injuries, in particular, can be caused by accidents, falls, athletic injuries, etc. Current methods of repair
include direct suturing of the 2 injured nerve ends or the use of autografts, when a nerve section is taken
from another area of the body. Both methods have a series of limitations which have led researchers to
study alternative methods of repair. Nerve guidance conduits may provide a viable solution because
they can be modified and adapted to the patient’s needs. Some conduits already exist on the market and
are manufactured using FDA-approved biomaterials. Poly(ethylene glycol) (PEG) is an FDA-approved
biomaterial not currently used in market-available conduits. It possesses many qualities that would
make it a desirable material for nerve regeneration. It does not interfere with activity of peptides that
can be used to make the material bioactive and biodegradable. It is also photocrosslinkable through
exposure to ultraviolet (UV) light. One such method that does this is stereolithography (SL). SL is an
additive manufacturing technology that runs a UV laser over the surface of a photocrosslinkable resin,
solidifying the resin into a desired shape. SL provides one of the best surface finishes of any additive
manufacturing technology. In the case of PEG, SL forms a hydrogel. This allows the material to
resemble soft tissue. A series of tests were conducted for this thesis to study the use of PEG in the
construction of nerve guidance conduits via SL.
First, it was important to test how growth factors can be integrated into a nerve guidance conduit
to promote neurite extension, improving the prospect of regeneration. For this, nerve growth factor
(NGF) was incorporated into PEG scaffolds through encapsulation and conjugation of the protein. The
rate of release of NGF by the scaffold was tested over a 35-day period using 2 molecular weights of
PEG. The bioactivity of NGF was tested by seeding PC-12 cells with it and analyzing neurite extension.
Then, cells were seeded directly on a PEG surface to test if they can attach to the material through the
use of a cell adhesion peptide, RGDS. In addition, NGF was added to already-attached cells to verify
that neurite extension can also be accomplished on a PEG surface. These results were compared to
those achieved by growing cells on tissue culture-treated plastic. In vivo tests were conducted by
implanting single-lumen and multi-lumen conduits into Sprague-Dawley rats.
vi

Histomorphological

analysis compared axonal regeneration in proximal, middle, and distal portions of the conduit to that
found in healthy, uninjured, nerve. These tests were also used to compare the efficiency of single and
multi-lumen conduits. Cell attachment to PEG may be increased if the surface area available for
attachment is increased. For this, an alternative construction method was studied using a modified SL
system. A commercial SL system was retrofitted in a biosafety cabinet and the optical system was
changed to decrease the diameter of the laser beam. The decrease in diameter would permit construction
of nerve guidance conduits of an increased number of lumens by reducing the diameter. Construction of
14, 16, and 18-lumen samples was attempted using this new, modified, SL system.
The NGF proved to be bioactive in that it promoted neurite extension in PC-12 cells. When
encapsulating NGF, a greater release was seen using a higher molecular weight of PEGda. On the other
hand, when conjugating NGF, a greater release was seen from a lower molecular weight. A quick initial
burst was present from all of the samples. RGDS did, in fact, produce attachment of cells to a PEG
surface. However, the amount of cells attached was less than that seen on tissue-culture treated plastic.
Addition of NGF promoted neurite extension on both surfaces with a greater percentage of cells
extending neurites on the PEG surface. This is most likely due to the fact that neurites extend better on
more flexible surfaces as less tension is required. In vivo tests showed that nerve regeneration can be
achieved by using SL-fabricated PEG conduits.

Upon histomorphological analysis, single-lumen

conduits yielded results comparable to controls as seen in axon diameter, myelin thickness, and total
number of fibers. On the other hand, histomorphological analysis of multi-lumen conduits could not be
achieved due to problems in the staining and sectioning of the sections. Finally, when using the
modified SL system, it was also possible to produce conduits with (or conduit sections) sections
containing as many as 18 lumens. Calculations of samples in a swollen state showed 7-lumen conduits
had a surface area of 125.6 mm2 while 18-lumen conduits had an increased surface area of 193.5 mm2.
Nerve injuries can be very debilitating and can interrupt a person’s lifestyle significantly. This
research studied SL as a means for constructing PEG nerve guidance conduits as an alternative to
current methods of repair. As a building technique, SL offers several advantages in the design and
finish of the product. Results achieved in this thesis demonstrated that PEG can be made bioactive
vii

through addition of RGDS, a cell adhesion peptide, and NGF, a protein that stimulates neurite extension.
In vivo tests showed that regeneration can be achieved using single-lumen conduits. More tests are
required to study regeneration using multi-lumen conduits as problems in the histological preparation
hindered the analysis of such. Multi-lumen conduits (containing up to 18 lumens) can, however, be built
using a laser of reduced diameter, increasing the surface area available for cell attachment. Although
more tests are required, the ability to regenerate injured nerves using SL is possible.
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Chapter 1: Introduction
1.1

THE NERVOUS SYSTEM
The nervous system is the system that allows the body to react to external and internal

environmental changes. It establishes coordination and integration of activities amongst other systems
in the body, such as that which occurs between the circulatory and respiratory systems. The nervous
system can be divided into two structural components: the central nervous system (CNS) and the
peripheral nervous system (PNS). The CNS consists of the brain and the spinal cord while the PNS
consists of exterior fibers that send impulses to and away from the CNS. There are two main cell types
making up the nervous system: neurons and neuroglia, also known as glial cells. Neurons are the
functional units of the nervous system [1]. They communicate with each other using a combination of
electrical and chemical signals. Because most neurons are electrically excitable, they can convey
electrical signals rapidly and accurately.

This is the way a human body organizes and directs

physiological responses. Neurons are composed of a cell body with dendrites, and an axon. Axons are
what carry the nerve impulses, known as action potentials, away from the cell body [2]. Large segments
of axon are insulated by a myelin sheath, formed by overlapping layers of myelin, a type of fatty
membrane made of lipid and protein [1].

Myelin serves two purposes: to increase the effective

transmembrane resistance and decrease the effective membrane capacitance. This greatly increases the
length constant of the axon membrane covered by myelin. Therefore, enhancing the efficiency with
which current spreads in a longitudinal direction. However, in order for this to happen, myelin must
leave some segments of the axon exposed. Such segments are known as nodes of Ranvier. Wrapped
segments of axon can range from 200 µm to 2 mm in length; whereas nodes of Ranvier are only about
10 µm. This results in an inconsistent propagation of action potentials along the axonal membrane.
Instead, action potentials are only produced in the nodes of Ranvier, resulting in a phenomenon known
as saltatory conduction. This greatly enhances the velocity of signal transmission. A single nerve can
contain many unmyelinated axons of different diameters.

As a result, signals travel at different

velocities within the same nerve [2]. The second cell type, neuroglia, are more abundant than neurons;
about five times more. They are present because they form the scaffolding of the nervous tissue. They
1

are nonneuronal and nonexcitable [1]. Two types of neuroglia are Schwann cells and oligodendrocytes.
Schwann cells are the cells that lay down myelin around axons in the PNS while oligodendrocytes do so
in the CNS. All of these components are illustrated in Figure 1.1.
As previously mentioned, cell bodies are surrounded by dendrites. Dendrites are branches that
serve as receivers to gather information from other neurons and carry them toward the cell body. At the
opposite end of a neuron, lie the axon terminals. The specialized location where a dendrite from a
neuron meets an axon terminal from another neuron is called a synapse [See Figure 1.1]. Presynaptic
and postsynaptic cells pass and receive information across a synapse, respectively. The majority of
synaptic transmission is done by chemical neurotransmitters, specific molecules released from the axon
terminals of a presynaptic neuron in response to an action potential in its axon [2].

Figure 1.1: Anatomy of a neuron. By courtesy of Encyclopaedia Britannica, Inc., copyright 2002; used
with permission [3].

2

1.1.1

The Peripheral Nervous System
The purpose of PNS is to connect peripheral structures to the CNS. Peripheral nerves are made

up of bundles of nerve fibers, their connective tissue coverings, and blood vessels. The neurolemma of a
myelinated nerve fiber consists of a myelin sheath surrounding an individual axon, along with the
Schwann cells forming such myelin. The neurolemma of unmyelinated nerve fibers consists of multiple
axons embedded within the cytoplasm of non-myelin-producing Schwann cells. Peripheral nerves are
protected by three types of connective tissue coverings and are therefore, fairly strong.

The

endoneurium surrounds the neurolemma cells and axons. The perineurium surrounds a fascicle, or
bundle of nerve fibers. Finally, the epineurium encloses a bundle of fascicles and also forms the
outermost covering of a nerve. It can also include fatty tissue, blood vessels, and lymphatics [1]. The
various connective tissue coverings can be seen in Figure 1.2.

P

F

BV
MA

(A)

BV
E

(B)
Figure 1.2: Arrangement of a Peripheral Nerve; (A) Illustration showing connective tissue coverings.
Used with permission [4]; (B) Cross-sectional view of a nerve, F = Fascicle, P = Perineurium, MA =
Myelinated axons, BV = Blood vessels, E = Epineurium
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1.1.2

Peripheral Nerve Injuries
While injuries to the spinal cord can have severe consequences, such as paraplegia or

quadriplegia, peripheral nerve injuries can have series results as well. They can occur as a result of
automobile accidents, work accidents, falls, athletic injuries, etc. Peripheral nerve injuries interfere with
the brain’s ability to communicate with muscles and organs. They are a significant source of morbidity
in trauma patients. According to a 10-year study conducted by Noble et al., peripheral nerve injuries
affect 2.8% of all trauma cases [5]. Each year in the U.S., approximately 360,000 people are affected by
upper extremity paralytic syndromes [6]. This, in turn, results in lost work due to days of restricted
activity and bed rest. The most severe form of injury is when a nerve is completely severed. Because it
is no longer receiving metabolic support from the cell bodies, the distal portion begins to degenerate
through a process known as Wallerian degeneration [7]. First, the cytoskeleton breaks down and the cell
membrane begins to dissolve. Then, Schwann cells shed their myelin lipids [8]. Although it is debated
that Schwann cells do not participate in clearance of myelin debris, studies conducted by Stoll, et al.
support evidence showing that Schwann cells, aided by phagocytic cells such as macrophages, clear
myelin and other axonal debris [9]. Following debris clearance, these cells can also produce cytokines
to enhance axonal regeneration. New axons are usually born at the nodes of Ranvier of existing axons.
Regeneration begins at the proximal end, continues in the distal direction, and is complete once axons
reach the distal target. Axonal regeneration in humans occurs at an approximate rate of 2 – 5 mm/day
[8] [See Figure 1.3].

Figure 1.3: Physiological response to a peripheral nerve injury. Used with permission [8].
4

1.1.3

Current Methods of Peripheral Nerve Repair
Recent technology has allowed for many advances in the repair of nerve injuries; two forms

being direct repair and autograft repair [10]. Neurorrhaphy, a type of direct repair, consists of direct
surgical reconnection of the proximal and distal nerve ends [See Figure 1.4 (A)]. Such repair can only
be performed when the defect is less than 5 mm [11]. It is not effective if the nerve gap is too large
because introducing tension into the nerve can result in loss of function [10]. Wall, et al. showed that
the tibial nerve can regain almost all function when stretched only by 6%. Yet, when stretched by 12%,
there is complete loss of function [12]. Autograft repair, on the other hand, uses a nerve graft taken
from a donor site [10] [See Figure 1.4 (B)]. Autografts are more likely to be biocompatible than
synthetic materials. For this reason, they are the current standard of care for peripheral nerve injuries
too large to be treated by direct repair [11]. However, there are several limitations to autograft repair.
There is always a risk for donor site morbidity such as scarring or loss of sensation. There is also a
limited supply of donor tissue, especially when treatment of long nerve gaps is required [11]. There is
no guarantee for full functional recovery at the site of injury. In fact, only about an 80% clinical
functional recovery rate is achieved through autograft repair [8].

Such deficiencies in direct and

autograft repair have led researchers to look for other methods to treat peripheral nerve injuries. A nerve
guidance conduit can provide a promising alternative to the previously mentioned methods [10, 11, 13].

(A)

(B)

(C)
Figure 1.4: Methods of peripheral nerve repair; (A) Direct surgical reconnection [7]; (B) Autograft nerve
repair [14]; (C) Nerve guidance conduit [7]. All images used with permission.
5

1.1.4

Nerve Guidance Conduits
Nerve guidance conduits are scaffolds used to guide nerve regeneration. They are typically

designed as tubular conduits to which nervous tissue can be sutured at each end. Unlike using an
autograft, they eliminate the need for a second surgical site. Therefore, donor site morbidity is not a
factor.

A nerve guidance conduit should possess three essential properties. It must be readily

manufactured having the desired dimensions, must be easily implantable, and must be easily sterilizable
[15]. In addition, there are other properties a conduit may possess to make it an ideal candidate for
nerve repair: biodegradability and porosity of its walls, controlled release of bioactive factors, the ability
to incorporate support cells, an internal matrix that allows for cell migration, intraluminal channels that
mimic the internal structure of fascicles, and electrical activity [See Figure 1.5] [15].

Figure 1.5: Properties of an ideal nerve guidance conduit. Used with permission [15].
Certain materials have already received approval by the US Food and Drug Administration
(FDA) for use in peripheral nerve repair. These include both natural and synthetic materials. The
Neurotube® is a conduit made of polyglycolic acid (PGA) that received FDA approval in 1999. It has a
degradation period of 3 months and works with gaps of 2-4 cm. The NeuraGen®, Neuroflex™, and
NeuroMatrix™ tubes are all made from type I collagen and were approved in 2001. NeuraGen® has a
6

36-48 month degradation period and can be used for gaps of 2-3 cm. On the other hand Neuroflex™,
and NeuroMatrix™ have a degradation period of 4-8 months and work for gaps of 2.5 cm. The
Neurolac® was approved in 2003. It is made from poly(α-lactide-ε-caprolactone) (PCL) and has a 16
month degradation. It works with gaps of 3 cm. The AxoGuard™ Nerve Connector is made from
porcine small intestine submucosa (SIS). It was also approved in 2003. It works with 10 mm gaps and
has a degradation period of 3 months.

Finally, the SaluTunnel™ Nerve Protector™, made from

polyvinyl alcohol (PVA), was approved in 2010. It is non-absorbable and works with 6.35 cm gaps
[16].
There are some downsides to working with these implants. The high rate of degradation of some
of these materials, such as PGA, type I collagen, and SIS, causes a contiguous reduction of short term
mechanical properties as well as acidic degradation products. On the other hand, conduits that degrade
over too long (NeuraGen®) or those that do not degrade at all (Nerve Protector™) may lead to nerve
compression and tension at the suture lines once regeneration has occurred. The Neurolac conduit,
made from PCL, is very rigid. Previous studies of this conduit have shown frequent needle breakage
during suturing. This may also lead to the nerve stumps being torn out of the conduit as a result of
inflexibility. Finally, natural materials, such as type I collagen or SIS, may cause undesirable immune
responses. Therefore, immunosuppressive drugs may be required. Batch-to-batch variations may also
diminish the reproducible performance of these devices [16].
1.2

STEREOLITHOGRAPHY
Stereolithography (SL) is an additive manufacturing technology in which three-dimensional (3D)

parts are built in a layer by layer basis when a laser beam scans the surface of a photocrosslinkable
liquid resin. First, a computer-aided design (CAD) of the desired part is created. The user must convert
the file into .stl format and import it into the SL system. In a commercial SL system, a large vat is filled
with liquid resin. A computer-controlled optical scanning system directs a helium-cadmium (HeCd)
ultraviolet (UV) laser via a specific path outlined by the CAD file. The laser cures a thin layer of resin
near the surface. The build platform is then lowered by an elevator and a sweeper blade coats a new
layer of resin on the surface. The laser travels across the surface again and a new layer is similarly
7

formed. The process continues until all of the layers are built and the part is finished. The vat can be
drained to remove the part for additional processing if necessary [17]. These components are illustrated
in Figure 1.6.
Lens
Laser

Scanning Mirror
Laser Beam

Vat
Sweeper Blade
Built Part
Build Stage
Photopolymer
Resin

Figure 1.6: Commercial set-up of a stereolithography system
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Optical
Assembly

HeCd Laser

Control
Center

Build
Chamber

(A)

(B)
Figure 1.7: 3D Systems SLA 250/50 (Valencia, CA); (A) Exterior view; (B) Modified mini vat
design. Used with permission [18].
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1.2.1

Mini Vat Design
The SLA 250/50 from 3D Systems (Valencia, CA) pictured in Figure 1.7 (A), was utilized for

most of the tests in the chapters that follow. The design of a typical SL system was not practical for use
in these tests as the vat that holds the liquid polymer was too large. Therefore, it was slightly modified
to use a mini vat [See Figure 1.7 (B)]. A keyed fixture was secured to the already existing elevator
platform. The mini vat consisted of two parts: a base and cylinder. The cylinder snaps into the base
creating a tight fit. The base then fits into the keyed fixture. When a slightly larger construction area
was needed, the cylinder was removed and the base was used on its own [18]. When using this vat, the
automated elevator movement was overridden. Because of this, new polymer was added manually
between each layer to raise the polymer level and allow for construction of a new layer on top of the
existing one. Prior to building a part, it was necessary to test the volume of polymer needed to ensure
good interlayer bonding.
1.2.2

Building Nerve Guidance Conduits by Stereolithography
Advances in photocrosslinkable biomaterials provide promising direction for the fabrication of

conduits using SL. SL is a highly accurate technology. It can obtain one of the best surface finishes
amongst additive manufacturing technologies [17]. Because SL systems work with CAD files, making
modifications to the design of a conduit is simple. For example, the number of lumens, lumen diameter,
conduit diameter, etc. can be changed within a brief period. The length of a conduit can also be changed
to accommodate the need of a patient by increasing or decreasing the number of layers that are built. A
CAD file can be changed to build several conduits at the same time. Critical exposure (EC) and
penetration depth (DP) are properties of every photopolymer. EC is the energy level required to change
the photopolymer from a liquid to a solid state while DP is the depth at which the irradiance becomes 1/e
times that at the surface [19].

By modifying the EC and DP values on the system, the user can also

modify the laser scan speed. It is important to use a speed appropriate to the type of photopolymer being
used. As some require longer UV exposure to photocrosslink, a slower laser scan speed is required.
The following equation, which gives the solidification shape along the laser-moving axis, shows the
relationship amongst these parameters:
10

(1.2 - 1) [19]

where
W0(z) is Gaussian half-width of the laser beam,
PL is laser power,
VS is laser scan speed,
EC is critical exposure,
DP is penetration depth.
1.3

STEREOLITHOGRAPHY MATERIALS

1.3.1

Poly(ethylene glycol)
Poly(ethylene glycol) (PEG) is a biocompatible material, approved by the FDA for human use

[20]. The material has been studied for use in numerous applications such as formation of PEG-protein
conjugates for pharmaceutical purposes, formation of PEG tethers for synthesis of biomolecules and
biological targeting, and surface modification to provide protein and cell rejecting properties.

In

hydrogel form PEG can be used for cell encapsulation, drug delivery, and wound covering [21]. It has
been studied for a variety of tissue engineering applications including those for regeneration of bone,
cartilage, and smooth muscle [22-24]. The safety of PEG for use in humans is dependent upon its
molecular weight. At low molecular weights (< 1,000 Da) the material can be oxidized into toxic diacid
and hydroxyl acid metabolites by liver enzymes, alcohol dehydrogenase and aldehyde dehydrogenase.
High molecular weight PEG, on the other hand, is excreted through glomerular filtration of the kidney
[25]. Typically, for tissue engineering purposes, molecular weights of 3,400 Da or 6,000 Da are used
[23, 24, 26].
Previous work has shown it is possible to build nerve guidance conduits from high molecular
weight PEG using SL [27]. Through acrylation or methacrylation of its endcaps, it can be chemically
modified into a photocrosslinkable material.

Such is the case of poly(ethylene glycol) diacrylate

(PEGda). Crosslinking is achieved when there is free-radical polymerization of the acrylate groups.
This takes place in the presence of a photoinitiator and UV light.
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The result is the formation of a

hydrogel that is stable over an extended period of time [28]. The chemical structures of PEG and
PEGda can be seen in Figure 1.8 (A) and (B). PEGda is a good candidate for conduit construction
because it possesses many of the previously mentioned properties required of a conduit material.
Because of its hydrophilic nature, the hydrogel chains absorb and retain water in an effort to reach
equilibrium [29]. When placed in liquid, PEGda scaffolds swell to a dimension that is 18 to 25% larger
than the original [18, 27]. For this reason, PEGda mimics soft tissue well. Arcaute et al. showed that
PEGda scaffolds can withstand the lyophilization and hydrogen peroxide sterilization processes;
therefore, making conduits readily available and easy to transport [27]. In addition, PEGda exhibits low
immunogenicity and antigenicity. It does not interfere with activities of enzymes or proteins [24, 26,
29].

Because of this, it can be made bioactive through addition of cell adhesion peptides or

biodegradable through addition of peptides that are susceptible to enzymatic attack, chemical
modification, or copolymerization [24, 26].
1.3.2

Irgacure 2959
Photoinitiators are light-sensitive compounds that can generate free radicals. Irgacure-2959 (I-

2959) is a commercially available photoinitiator.

Its chemical name is 2-hydroxy-1-[4-

hydroxyethoxy)phenyl]-2-methyl-1-propanone [See Figure 1.8 (C)]. Photoinitiators commonly used in
the formation of hydrogels, typically exhibit low cytotoxicity. This makes it possible to encapsulate
viable cells within a hydrogel mesh, if desired [30].

n
Poly(ethylene glycol)
(A)

n
Poly(ethylene glycol) diacrylate
(B)
2-hydroxy-1-[4-hydroxyethoxy)phenyl]-2-methyl-1-propanone
(C)

Figure 1.8: Chemical structures; (A) PEG; (B) PEGda; (C) I-2959; [31].
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Chapter 2: Controlling Release of Nerve Growth Factor by a Poly(ethylene glycol)
Scaffold
2.1

INTRODUCTION

2.1.1

Nerve Growth Factor
Nerve growth factor (NGF) is a neurotrophin naturally produced by Schwann cells that is

necessary for signaling in peripheral nerve regeneration [32]. NGF is a 140 kDa polypeptide composed
of three protein subunits: α, β, and γ. The β subunit is the one responsible for the neurotrophin effects
and is also known as 2.5S NGF. This subunit is a dimer with a molecular weight of 26 kDa [33]. The
dimeric structure can be seen in Figure 2.1. NGF promotes cell survival, differentiation, and neurite
extension [8]. A neurite is anything that sprouts from the cell body of a neuron: an axon or a dendrite.
NGF also has the ability to protect neurons from death at sites of injury [34]. It has already been
demonstrated that poly(ethylene glycol) (PEG) is a material that is receptive to addition of proteins and
enzymes as it does not interfere with their activity [29]. NGF can therefore, be incorporated into PEG
nerve guidance conduits, increasing their ability to guide complete nerve regeneration.

Axonal

regeneration in humans occurs at an approximate rate of 2 – 5 mm/day [8]. The time necessary for
regeneration is dependent upon the length of the site of injury. This is because regeneration occurs from
the proximal end to the distal end and is complete once axons reach the distal target. If the scaffold
material releases the NGF too soon, before full regeneration takes place, there may not be enough left
during the later stages of regeneration.

Therefore NGF release by the polymer must occur in a

controlled manner [35].

Figure 2.1: Structure of 2.5S NGF. Used with permission [36].
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2.1.2

NGF in Tissue Engineering Scaffolds
Several methods have been tested for incorporating growth factors into a tissue engineering

scaffolds. One method, as done by Evans et al., incorporates Schwann cells into guidance conduits
rather than adding the growth factors directly [37].
microspheres [38-40].

Others have tested the use of polymeric

For example, Xu et al. used biodegradable poly(phosphoester) (PPE)

microspheres to encapsulate NGF and achieve controlled delivery over a 10-week period of sciatic
regeneration [41]. Lee et al., on the other hand, tested regeneration along the sciatic nerve of a rat by
using a fibrin-based matrix to control the delivery of NGF based on its affinity to interactions with
heparin-binding sites [35].
2.1.3

PC-12 Cell Line
The rat pheochromocytoma cell line (PC-12) is derived from an embryonic adrenal tumor.

These cells are commonly used in neuronal experiments because upon incubation with NGF they are
differentiated from chromaffin-like cells to sympathetic neuron-like cells. As a result, they extend
neurites and express neuron-specific proteins. Other morphological changes include elaboration of
microtubule arrays in neurites and the appearance of synaptic vesicles [42].
2.1.4

Objective
This research utilized 2 methods of incorporating NGF into a poly(ethylene glycol) diacrylate

(PEGda) disk-shaped scaffold, encapsulation of NGF within the hydrogel matrix and conjugation of
NGF to the hydrogel molecules. This was achieved using 2 different molecular weights of PEGda, 3.4
kDa and 6 kDa. The objective was to test which method would best serve to obtain controlled release of
NGF over a 30-day period. Prior to testing the rate of release, the protein’s bioactivity was tested by
seeding PC-12 cells with it and analyzing neurite extension.
2.2

MATERIALS AND METHODS

2.2.1

NGF Reconstitution
The NGF for these tests was obtained in dehydrated form from Promega (mNGF, 2.5S, Madison,

WI). It was reconstituted at a concentration of 1 µg/µL with RPMI-1640 (Sigma-Aldrich, St. Louis,
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MO) containing 1% Bovine Serum Albumin (BSA) and kept in microcentrifuge tubes at -20°C until
further use.
2.2.2

NGF Bioactivity Test
PC-12 cells (ATCC, Manassas, VA) were maintained at 37°C, 90% relative humidity, and a 5%

CO2 environment. They were kept in complete RPMI-1640 media supplemented with 10% Horse
Serum, 5% Fetal Bovine Serum, 1% glutamine-penicillin-streptomycin (GPS), 10 mM HEPES, and 1
mM sodium pyruvate. The cells were primed with NGF at 50 ng/mL 2 days before the start of the
experiment. They were then transferred onto 24-well plates made of tissue-culture treated polystyrene at
103 cells/well. One mL of complete media containing either 50 ng/mL, 100 ng/mL, or 150 ng/mL of
NGF was added per well. As a control, some cells were kept in media without NGF. The plates were
incubated under the same conditions as before (37°C, 90% relative humidity, and 5% CO2). The media
was removed after 3 days and replaced with fresh media containing the same NGF concentrations. All
of the steps were completed in a biosafety cabinet (Purifier Class II, Labconco, Kansas City, MO) to
reduce the risk of contamination. Low (100x) and high (200x) magnification images were taken 7 days
after the initial seeding using an inverted microscope (Leica DMIRB, Leica Microsystems, Germany)
with a charge-coupled device camera (Retiga 2000S Fast 1394, QImaging Corp., Canada).
2.2.3

PEGda Preparation
All PEGda solutions were stored at -20°C and allowed to reach room temperature, approximately

1 hour before preparation. Two PEGda preparations were made using either 3.4 kDa or 6 kDa. At a
molecular weight of 3.4 kDa, PEGda is commercially available through Laysan Bio Inc. (Arab, AL). At
6 kDa it was received from the University of Utah’s Department of Bioengineering and synthesized via
a process outlined in Gunn et al. [26]. Irgacure 2959 (I-2959, Ciba Specialty Chemicals, Tarrytown,
NY) was used as the photoinitiator and 1X Phosphate Buffered Saline (PBS) as the solvent. The
solutions were prepared by adding 1 g of PEGda and 0.0167 g of I-2959 to 2.33 mL of PBS. This
yielded a 30 wt% concentration of PEGda and a 0.5 wt% concentration of I-2959. The solution was
then placed on a shaker until the polymer and photoinitiator were completely dissolved (~2 hours). An
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amber-colored glass vial was used for preparation of the solution to reduce the amount of ambient light
exposure and prevent early photocrosslinking.
2.2.4

NGF Conjugation
To conjugate NGF to PEGda, a Michael-type addition reaction was conducted. In this reaction, a

free thiol or primary amine on NGF reacts with an acrylate on PEGda under slightly basic conditions.
For this, 4.4 µg of PEGda were dissolved in 2 mL PBS and syringe filtered to eliminate any clumps.
This was done for both, the 3.4 kDa and 6 kDa, solutions. For the 3.4 kDa solution, 9 µL of the newly
mixed PEGda solution and 26 µL of NGF were added to 65 µL of PBS (pH 7.4) in a new
microcentrifuge tube. For 6 kDa, 5.27 µL of PEGda and 10 µL of NGF were added to 84.73 µL of PBS
(pH 7.4) in another microcentrifuge tube. These quantities yielded a 1:5 ratio of NGF to PEGda for each
respective molecular weight.

Both tubes were covered with aluminum foil and left undisturbed for 2

hours at room temperature.
2.2.5 NGF Encapsulation
For encapsulated NGF, the protein was added to PEGda while the polymer was still in liquid
form. This was done so that upon exposure to UV light, the PEGda molecules would crosslink forming
a hydrogel mesh that encapsulated the NGF within. Calculations were made so each disk would contain
500 ng of NGF.
2.2.6

Disk Construction
Disk-shaped samples were designed using SolidWorksTM [See Figure 2.2]. They were built

using the 3D Systems® model 250/50 (Valencia, CA).

Prior to using the SL equipment, it was

disinfected thoroughly with antibacterial wipes to prevent contamination during the construction
process. The laser was allowed to reach maximum power (16-17 mW). The disks were built using 600
µL of PEGda at a laser scan speed of 8.085 in/s. Batches of 6 disks of each material were built and
immediately suspended in 1 mL of RPMI-1640 media in ultra-low attachment microcentrifuge tubes.
One disk was housed per tube. This media did not contain any of the supplements previously mentioned
for cell culture. Unlike other PEGda samples, these disks were not rinsed in deionized water after
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construction so as not lose any of the NGF within the scaffold. The tubes were incubated at 37˚C in a
5% CO2 environment at 90% humidity [See Figure 2.3]. The media was collected and replaced with
fresh RPMI-1640 at various time points following initial disk construction: 2 hours, 4 hours, 8 hours, 12
hours, 24 hours, 48 hours, 5 days, 7 days, 10 days, 15 days, and 30 days. The media collected at each
time point was stored in microcentrifuge tubes at -20°C until ready for analysis with ELISA.

Figure 2.2: Disk design for NGF Release

Figure 2.3: Disks incubated in microcentrifuge tubes
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2.2.7

ELISA
The media collected at the various time points was analyzed using an enzyme-linked

immunosorbent assay (ELISA), a 3-day procedure used to determine the NGF concentration. One
ELISA was conducted for each of the 4 PEGda test groups: 3.4 kDa with encapsulated NGF, 3.4 kDa
with conjugated NGF, 6 kDa with encapsulated NGF, and 6 kDa with conjugated NGF. The ELISA kit
used was the Promega NGF Emax® ImmunoAssay System (Madison, WI) and the manufacturer’s
instructions were followed. All reagents used for this procedure were provided in the kit unless
otherwise indicated. Each ELISA was carried out on a 96-well plate. First, a carbonate coating buffer
was prepared consisting of 0.025M of both, sodium bicarbonate and sodium carbonate (Sigma-Aldrich,
St. Louis, MO). The buffer was raised to a pH of 9.7 and was used to dilute Polyclonal Antibody (AntiNGF-pAb). This solution was used to coat the surface of the plate [See Figure 2.4 (1)]. The plate was
sealed using Parafilm Wrap and incubated overnight at 4°C. The plate was washed 3 times using a
TBST wash buffer consisting of 20 mM tris-hydrochloride (Avantor, Performance Materials, Center
Valley, PA), 150 mM sodium chloride (Avantor, Performance Materials, Center Valley, PA), and 0.05%
(v/v) Tween® 20. Block & Sample 1X Buffer was used to block any surface of the plate where
antibody did not bind [See Figure 2.4 (2)]. A 1-hour incubation period at room temperature was
completed and the contents of the plate were washed once with TBST wash buffer. Two columns were
designated for the NGF standard curve. NGF was diluted in Block & Sample Buffer at concentration of
250 pg/mL and placed in the top 2 wells of these columns. 1:2 dilutions were performed down the plate
until the standard columns were full. The various samples were added to the remainder of the wells at
1:40, 1:80, and 1:160 dilutions. Only the 2-hour samples were diluted at 1:200, 1:400, and 1:800 as it
was believed the NGF concentration would be much higher at this time point. The plate was sealed and
incubated for 6 hours at room temperature on an orbital shaker (DS-500, VWR, Radnor, PA) at 500 rpm.
This allowed for the binding of NGF to the Anti-NGF-pAb already bound to the surface [See Figure 2.4
(3)]. The wells were washed 5 times with TBST wash buffer. Monoclonal antibody (Anti-NGF mAb)
was diluted in Block & Sample 1X Buffer and added to the plate to capture the NGF [See Figure 2.4
(4)]. The plate was sealed and incubated overnight at 4°C. The following day the wells were washed 5
times with TBST was buffer. A species specific antibody conjugated to horseradish peroxidase (Anti18

Rat IgG, HRP Conjugate) was diluted in Block & Sample Buffer and added to each well to detect the
Anti-NGF mAb [See Figure 2.4 (5)]. The plate was incubated for 2.5 hours at room temperature with
shaking at 500 rpm. The plate was washed 5 times with TBST wash buffer and TMB One Solution was
added to each well [See Figure 2.4 (6)]. After 10 minutes, 1N hydrochloric acid (EMD Millipore,
Billerica, MA) was added to each well to stop the reaction. The absorbance was recorded at 450 nm on
a VersaMax Microplate Reader (Molecular Devices, Sunnyvale, CA) within 30 minutes of adding the
acid. An NGF standard curve was prepared and the samples were read based on that curve as the
amount of NGF is proportional to the color generated in the oxidation-reduction reaction.
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Figure 2.4: Order of steps in ELISA Procedure
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2.2.8

ELISA Results Interpretation
Once the plate was read, the standard curve was graphed using the absorbance values obtained.

An R2 value closest to 1 was used to find the straightest possible line amongst the points. The equation
for that line was then used to obtain the NGF concentration of the test samples using the known
absorbance values. This was done by solving for the value x. This value was then multiplied by the
dilution factor and averaged with the other dilutions of that sample to obtain the final amount of NGF
released for that specific time point. Figure 2.5 shows an example of one of the standard curves used for
these tests.

(A)

(B)
Figure 2.5: Example of an NGF standard curve (A) Curve displayed using all 8 values; (B) Lower 6
values used to obtain a formula for the straightest possible line (R2 value closest to 1)
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2.3

RESULTS

2.3.1

NGF Bioactivity
The results obtained from seeding cells without any NGF can be seen in Figure 2.6. These

images show minimal to no neurite extension. On the other hand, cells seeded with NGF did, in fact,
promote neurite extension in the cells after 7 days. Therefore, its bioactivity was proven. Although
cells were seeded with 3 different NGF concentrations, this did not have great effect on the number of
cells extending neurites nor on the length of such neurites. Therefore, a concentration of 50 ng/mL of
NGF is enough to achieve good, overall, extension.

Figure 2.6: Low and high magnification images of PC-12 cells after 7 days without NGF exposure
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50 ng/mL of NGF

100 ng/mL of NGF

150 ng/mL of NGF
Figure 2.7: Low and high magnification images of PC-12 cells after 7 days of NGF exposure at various
concentrations: 50 ng/mL, 100 ng/mL, and 150 ng/mL. Neurites are indicated by arrows.
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2.3.2

NGF Release
Upon addition to the plate, TMB One Solution turned each well blue. The intensity of the color

correlated with the concentration of NGF within that well. As shown in image (A) of Figure 2.8, the
darkest blue was seen in the first and last 2 columns. The first 2 columns contained the media collected
at the 2 hour mark, where the highest release of NGF was expected. The last 2 columns housed the NGF
standard values used to make the standard curve. The NGF concentration in the standard was highest in
the top wells. As HCl was added, the wells turned yellow immediately. The intensity of the yellow
color is what was read by the plate reader to yield the absorbance of the solution in every well.

(C)

(A)

(B)
Figure 2.8: ELISA Plate; (A) After addition of TMB Solution; (B) During addition of HCl to stop
reaction; (C) After addition of HCl
The total NGF release over a 30-day period is illustrated in Figure 2.9. All of the disks built
contained 500 ng of NGF at the start of the experiment. The highest release was seen by PEGda at 3.4
kDa with conjugated NGF at 154.2 ng (30.8% of the total). This was then followed closely by the 6 kDa
samples with encapsulated NGF at 150.2 ng (30.0%). Far behind was the 6 kDa with conjugated NGF
at 58.2 ng (11.6%). The lowest cumulative release was seen by 3.4 kDa with encapsulated NGF at 22.8
ng (4.6%). All four formulations showed a similar initial burst with the greatest release occurring within
the first 24 hours. After about 7 days, very small quantities of NGF were released. The initial 24-hour
burst is illustrated more clearly in Figure 2.10. For example, in the samples with the highest release,
72.2% of that release occurred during the initial 2 hours. In the lower 2 samples, 6 kDa with conjugated
NGF and 3.4 kDa with encapsulated NGF, there is not much release after that 2-hour marker.
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Figure 2.9: Cumulative NGF release over a 30-day period

Figure 2.10: Cumulative NGF release during initial 24 hours
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2.4

DISCUSSION
PEG has been studied for use in nerve regeneration techniques for its versatility in regards to

addition of growth factors and other peptides. NGF is a growth factor that may improve regeneration
because it promotes neurite extension in cells.

The protein must be integrated into the nerve

regeneration scaffold in a way that release of the protein occurs in a controlled manner. A controlled
release is best because it provides sufficient NGF for the duration of recovery. Two methods of
incorporating NGF into a PEGda scaffold were tested here, encapsulated NGF and conjugated NGF,
using 2 molecular weights of the polymer, 3.4 kDa and 6 kDa.
NGF which was encapsulated during photocrosslinking is released by simple diffusion. A higher
overall amount was released from the higher of the 2 molecular weights. This is due to the number of
acryl groups in each one. PEGda at 3.4 at 30 wt% has an acryl group molarity of 0.25 while 6 kDa at
the same concentration has an acryl group molarity of 0.10. The higher the molarity of acryl groups, the
more crosslinking that occurs during UV exposure. This yields a more complex hydrogel mesh which in
turn, blocks the diffusion of NGF. Encapsulated NGF may be useful when the injury gap is short and an
initial burst of protein is desired. As an alternative, NGF was covalently conjugated to each of the 2
molecular weights by producing a hydrolytically degradable ester bond between NGF and PEGda. This
was done in hope that this may slow down the release due to the extra time it takes to break that bond.
Once the bond is broken, NGF is free to diffuse as with its encapsulated counterpart. Therefore, the
release would rely on the rate of diffusion as well as the rate of hydrolysis. This was not the case,
however. The highest release from all of the samples was seen in the 3.4 kDa, conjugated, preparation.
This also contradicted the previous argument which stated that lower molecular weights yield less
diffusion. It is possible that not all of the NGF conjugated to PEGda during the addition reaction. This
would allow a high initial burst of unconjugated NGF. It may also mean that the rate of hydrolysis was
not slow enough to endure past the 2-hour time point, especially in NGF conjugated near the surface.
None of the samples released the total 500 ng of NGF. The sample with the greatest release only
released 30.8% of the total. It is possible that the NGF is so trapped within the hydrogel network that it
may take much longer than 30 days for the total amount to be released. Previous work incorporated the
protein BSA into PEGda microspheres at a high polymer molecular weight (575 kDa). Only about 20%
25

of the total amount of protein was released by day 30. It took 280 days for the total amount of BSA to
be released [43]. On the other hand, when using a lower molecular weight (10 kDa), as was done in
West et al., 100% of the BSA was released in 5 days [44]. As a reference, BSA is a 66 kDa protein
while NGF is 26 kDa. NGF should, therefore, be diffused with greater ease.
Several modifications can be made to acquire better results if the experiment is to be repeated.
Running the experiment for a much longer amount of time (~ 9 months) may make 100% release of the
protein possible. However, this may not be plausible given that nerve regeneration occurs at 2 - 5
mm/day and it may not take that long for full regeneration. On the hand, including biodegradation
factors in the PEGda scaffold may allow total release of the protein over a shorter period of time. That
is, the amount of time necessary for degradation of PEGda. Future tests are also necessary to determine
how much of the protein actually does conjugate to the PEGda molecules.
2.5

CONCLUSIONS
PEGda provides much promise for construction of nerve guidance conduits. It is a nonreactive,

biocompatible, material to which NGF may be incorporated. It is clear that NGF promotes cellular
neurite extension in addition to some of its other functions. Therefore, it is important to achieve
controlled release of NGF so that the protein will be available for the entire duration of nerve
regeneration. For encapsulated NGF, a greater release was seen using a higher molecular weight of
PEGda. On the other hand, for conjugated NGF, a greater release was seen from lower molecular
weight. A quick initial burst was present in all of the samples. This may only be desirable when
working with short injury gaps as the time of regeneration is dependent upon the length of the injury.
For longer gaps, conjugated NGF may yield better results once it is determined how to best conjugate all
of the protein.
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Chapter 3: Testing Cell Attachment to a Poly(ethylene glycol) Surface Using RGDS
as a Cell Adhesion Peptide
3.1

INTRODUCTION

3.1.1

RGDS
Poly(ethylene glycol) (PEG) is an excellent material for tissue engineering purposes because it is

essentially a blank canvas. By nature, PEG is a nonadhesive property [45]. However, it can be made
bioactive through covalent attachment of cell adhesion peptides. Cell adhesion peptides allow for the
attachment of a cell to a polymer by binding to integrins or other transmembrane receptors, located
along the surface of the cell membrane.

This is illustrated in Figure 3.1.

A peptide commonly

conjugated to PEG is RGDS, which consists of the following amino acid sequence: Arginine - Glycine Aspartic acid - Serine [See Figure 3.2]. RGDS is the binding site of fibronectin. Small peptide
sequences are preferred to entire proteins because they are easier to manufacture and can withstand
harsher processing conditions [26]. Aside from its use in neural regeneration techniques, RGDS has
been used in a variety of tissue engineering applications such as regeneration of smooth muscle, bone,
and cartilage, as well as wound healing [24, 46-48]. In addition to PEG, RGDS has been tested as a cell
adhesion peptide for other scaffold materials including, but not limited to, polyvinyl alcohol (PVA),
poly(propylene fumarate-co-ethylene glycol) (P(PF-co-EG)), polycaprolactone (PCL), and silk
scaffolds, [47, 49-51].
Cell Membrane
Cell

RGDS

RGDS

RGDS

Transmembrane
Receptor

Polymer

Figure 3.1: Polymer-cell adhesion using cell-adhesion peptides
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Cell Adhesion
Peptide

Arginine

Glycine

Aspartic Acid

Serine

Figure 3.2: Chemical structure of RGDS [52]
3.1.2

Nerve Growth Factor
Nerve growth factor (NGF) is a neurotrophin naturally produced by Schwann cells that can be

incorporated into poly(ethylene glycol) diacrylate (PEGda) nerve guidance conduits, increasing their
ability to guide complete nerve regeneration. NGF promotes neurite extension. A neurite is anything
that sprouts from the cell body of a neuron, such as an axon or a dendrite. Neurite extension has
previously been achieved on hydrogels [26]. Upon interaction with NGF, PC-12 cells, like the ones
used here, differentiate. This means that they show neuron-like behaviors, including neurite extension
[42]. Aside from being able to attach cells to a hydrogel surface, it is important that such cells have the
capacity to extend neurites. This increases the prospect of full regeneration.
3.1.3

Tissue Culture-Treated Polystyrene
Vessels and plates used for cell culture can be treated to improve cell attachment. One of 2

processes can be used, corona discharge or gas-plasma, to generate highly energetic oxygen ions. These
ions then attach to the polystyrene chains on the surface making them hydrophilic and negatively
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charged upon addition of cell culture media. The higher the oxygen content on the surface, the more
hydrophilic, the better it is for cell attachment and cell spreading [53].
3.1.3

Objective
The objective of the experiments outlined in this chapter was to test the cell attachment

properties of RGDS on a PEGda surface. For this, RGDS was covalently bound to PEGda and diskshaped scaffolds were photocrosslinked by stereolithography (SL). Cells were seeded on the surface of
these scaffolds in 24-well plates to evaluate cell attachment and viability. Additional cells were seed
directly onto the polystyrene surface of the plates and used as a control. NGF was added to test if
neurite extension could be achieved by cells seeded on a PEGda surface.
3.2

MATERIALS AND METHODS

3.2.1. PEGda Solution Preparation
A solution of commercially available 3.4 kDa PEGda (Laysan Bio Inc., Arab, AL) was prepared
at a 30 wt% concentration.

I-2959 (Ciba Specialty Chemicals, Tarrytown, NY) was used as a

photoinitiator at 0.5 wt% concentration. Prior to preparing the solution, PEGda was stored at -20°C. It
was taken out of storage and allowed to reach room temperature, approximately 1 hour before solution
preparation. An amber-colored glass vial was always used for preparation of the solution to reduce the
amount of ambient light exposure and prevent photocrosslinking. The solution was then placed on a
shaker until the polymer and photoinitiator were completely dissolved.
3.2.2

RGDS-PEG Conjugation
RGDS (Sigma-Aldrich, St. Louis, MO) was conjugated to 3.4 kDa Acryloyl-PEG-N-

hydroxysuccinimide (ACRL-PEG-NHS, Laysan Bio, Arab, AL) at a 2:1 peptide to polymer ratio. This
was done by first preparing a 50 mM sodium bicarbonate (NaHCO3) buffer and raising it to a pH of 8.5.
Buffer (230 µL) was added to each of 7 vials containing 10 mg of RGDS. The contents of all vials were
combined into a single 15 mL microcentrifuge tube and vortexed. An additional 230 µL of buffer were
used to collect any remaining RGDS from the vials. Buffer (3.22 mL) was then used to dilute 1.095 g of
ACR-PEG-NHS and the solution was vortexed. The polymer was added to the peptide in a dropwise
fashion, adding 1 or 2 drops and swirling. Once the polymer solution was consumed, the mixture was
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transferred to a 50 mL microcentrifuge tube in case of expansion of the contents in the freezer. An
additional 500 µL of buffer were used to collect any solution remaining in the previous vial. The
solution was placed on an orbital shaker for 2 hours at room temperature and frozen overnight at -80 °C.
The cap was removed and a Kim wipe was secured at the mouth with a rubber band. The contents were
lyophilized until dry. Any clumps were broken up with a spatula and the tube was placed in the freezer
at -20 °C until further use. Prior to sample fabrication, the concentration of RGDS was stabilized to 25
mg/mL with additional PEGda.
3.2.3

PEGda Disk Fabrication
The disk-shaped PEG samples were designed using SolidWorksTM. The diameter of each well in

a 24-well plate is 15.6 mm. By using a Dimensional Swelling Factor of 1.20, it was calculated that the
disks needed to be fabricated at a diameter of 13 mm so they would swell to 15.6 mm and fit tightly
within the wells. All disks were built using the 3D Systems® model 250/50 (3D Systems, Valencia,
CA). Prior to using the equipment, it was cleaned thoroughly with antibacterial wipes to prevent
contamination during the construction process. The laser of the SL system was allowed to reach
maximum power (~16-17 mW). The disks were built using 600 µL of PEGda solution at a previously
established laser scan speed of 8.085 in/s. Each newly polymerized disk was immediately placed in
deionized water in an ultra low attachment 24-well plate to remove any unreacted material and allow the
disks to reach equilibrium swelling. One disk was built at a time, totaling 6 disks.
3.2.4

Cell Seeding
PC-12 cells for this experiment were obtained from ATCC (Manassas, VA). Prior to seeding,

cells were maintained in a 37°C, 90% relative humidity, and 5% CO2 environment. All of the following
steps were completed in a biosafety cabinet to reduce the risk of contamination. Two hours after
fabrication, the 6 disks were moved from deionized water to Phosphate Buffered Saline (PBS). Because
PBS is a buffer, there is less risk for pH changes. After 48 hours, these 6 disks were moved to an ultra
low attachment 24-well polystyrene plate and placed in complete RPMI-1640 media (Sigma-Aldrich, St.
Louis, MO) supplemented with 10% Horse Serum, 5% Fetal Bovine Serum, 1% glutamine-penicillinstreptomycin (GPS), 10 mM HEPES, and 1 mM sodium pyruvate. These were incubated under the
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same conditions for 4 days. The media was removed and rubber o-rings, sterilized in 10% ethanol, were
placed on top of each disk. This was necessary to create a seal that would prevent the cells from
attaching to the floor of the well instead of the disk. A concentration of 104 cells was seeded on each of
the 6 disks. As a control, 104 cells were also seeded in 6 wells of a tissue culture treated 24-well plate
made of polystyrene. Both plates were incubated as before. The cell seeding process can be seen in
Figure 3.3 (A).
3.2.5

Addition of NGF
After 3 days, the media was removed from each of the 12 wells. Of the 6 wells containing PEG

disks, 3 were given complete RPMI-1640 containing 220 ng/mL of NGF. The other 3 were given
complete media without NGF. The same was done for the cells growing on tissue culture-treated
plastic. After an additional 2 days, the media was replaced and the NGF concentration was increased to
638 ng/mL in the same 6 wells. Addition of NGF is illustrated in Figure 3.3 (B).
3.2.6

Histomorphological Analysis
Seven days after the initial cell seeding, the cells were viewed using an inverted microscope

(DMIRB, Leica Microsystems, Germany) and images were taken with a charge-coupled device camera
(Retiga 2000S Fast 1394, QImaging Corp., Canada). Three images were taken of each well containing
NGF at 100x magnification, totaling 9 images for analysis on each of the 2 surfaces. Cell counts were
conducted to determine the number of cells attached to the PEGda surface versus the plastic surface. In
addition, the number of cells showing neurite extension was recorded. Only neurites longer than the cell
body they had extended from were considered in these counts. A two-sample t-test was used to compare
results of single-lumen samples. Equal variances were assumed. A p value lower than 0.05 was
considered statistically significant. Data are presented as mean
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standard deviation.

Cells
Rubber
O-Ring
PEGda Disk

Top-View

(A)

Ultra-Low Attachment Plate
Cells on PEG Disks

Side-View

Tissue Culture-Treated Plate
Cells on Plastic

NGF in Media

(B)
Figure 3.3: Cell adhesion procedure; (A) Cell seeding on 24-well plates; (B) Addition of NGF
3.3

RESULTS

3.3.1

Cell Attachment and Neurite Extension
Cell attachment to the PEGda surface after 7 days was good.

Cells were still alive and

reproducing on both surfaces. This is visible in the images in Figure 3.4 at 200x. There were, however,
what appeared to be large floating particles (encircled in red) surrounding cells seeded on the polymer.
Cells in wells containing NGF appeared to be better attached. There was also better neurite extension on
the PEGda surface as compared to the plastic surface. The neurites were longer and there were several
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cells with 3 or more extensions. Of the total cells counted, 11 cells on the PEGda surface had 3 or more
neurite extensions compared to only 5 on the plastic surface.

(B)

(A)

(D)

(C)

Figure 3.4: Cell growth after 7 days (200x); (A) Cells on PEG surface; (B) Cells with 4-day NGF
exposure on a PEG surface; (C) Cells on tissue culture-treated plastic; (D) Cells with 4- day NGF
exposure on tissue culture-treated plastic; (black arrows indicate neurite extensions and red circles
indicate paticles)
Figure 3.5 compares the cell attachment on a PEGda surface versus tissue culture-treated plastic.
Overall, cell attachment was greater on plastic than on PEGda. The average number of cells on a PEGda
surface was 5,778 ± 2,571 per cm2 whereas on plastic it was 8,808 ± 2,653 per cm2. Both sets of
samples contained NGF; therefore, this was not a factor. There was a statistically significant difference
amongst the results.
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Figure 3.5: Average cell attachment on PEGda disk vs. tissue culture-treated plastic with NGF present
in both cases; #: Difference is statistically significant, p<0.05
Figure 3.6 compares the neurite extension present on either surface. Only samples with NGF
present in the media were considered. Image (A) shows the percentage of cells extending at least 1
neurite. A greater percentage of cells were extending neurites on the PEGda surface, 22% ± 6.0%, than
the plastic surface, 10% ± 5.5%. Image (B) illustrates the average density of cells extending neurites per
cm2. The PEGda disks had an average density of 1,160 ± 382 cells with neurites per cm2. The tissue
culture-treated plastic only had an average density of 737 ± 160 cells with neurites per cm2. There was a
statistically significant difference amongst the results in both graphs.

(A)
(B)
Figure 3.6: Neurite extension; (A) Percentage of cells extending neurites; (B) Density of cells extending
neurites per image area; #: Difference is statistically significant, p<0.05
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3.4

DISCUSSION
The decision to use RGDS as the cell adhesion peptide for this research was due in part to

previous work conducted by Gunn et al. They evaluated 3 different peptides to determine which worked
best for nerve regeneration purposes using a PEG scaffold. Aside from RGDS, they tested Tyr-Ile-GlySer-Arg (YIGSR) and Ile-Lys-Val-Ala-Val (IKVAV). While RGDS is found in fibronectin, YIGSR and
IKVAV are both found in laminin. They too incorporated growth factors to evaluate which peptide
showed greater sprouting of neurites from cells. Although all 3 peptides demonstrated good cell
attachment, the greatest amount of neurite extension was seen using RGDS [26]. The cell attachment
tests presented here yielded helpful results. Good cell attachment was seen on both surfaces, meaning
the RGDS peptide was working. Cell growth was greater on tissue culture-treated plastic than on the
PEGda surface. However, in the samples containing NGF, PEGda provided a better surface for neurite
extension as a higher percentage of cells extended neurites. Yet, neurite extension was low considering
the concentration of NGF in each well was very high. Gunn et al., tested PEG surfaces at different
concentrations. They noticed that the number of neurites increased as the flexibility of the material
increased [26]. Although cells for the present research were only seeded on one PEGda concentration,
they were also seeded on polystyrene, a stronger, less flexible, material. Like them, the cells showed
greater neurite extension on the more flexible of the two materials, the hydrogel. Stronger, less elastic,
materials, like the plastic surface of a 24-well plate, may require the neurites to exert more tension when
they move. On the other hand, a material that is too elastic may not be strong enough to support
attachment and extension. A PEGda surface at the 30 wt% concentration used, mimics soft tissue well,
allowing for good neurite extension.
Dark particles were seen surrounding cells in the media. The original hypothesis was that these
particles were cell waste products. Replacing the culture media every 2-3 days is necessary to remove
waste products, replenish nutrients, and keep the correct pH. However, through further observation, it
was determined these were gas bubbles. Therefore, a gas release occurred as the result of the interaction
between the PEG, the PC12 cells, and the RGDS used to bind the two. These bubbles are seen in much
higher number on the cells seeded on the PEGda surface. Only a few very small bubbles were seen in
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wells of cells seeded on plastic. NGF was not the cause of the gas exchange because bubbles were seen
in wells without NGF as well. Further studies are necessary to evaluate the meaning of these bubbles
and their effect on cell attachment and neurite extension.
3.5

CONCLUSIONS
Based on the results, it can be concluded that PEGda does provide a suitable surface for cell

attachment. RGDS provided an anchor for cells to attach the polymer and grow. Although neurite
extension was low considering the concentration, it is highly likely that this is a consequence of
mistreated NGF and human error. If the experiment is repeated, it is best to use fresh NGF to ensure
neurite extension. Yet, the same NGF was used for growth on both surfaces and better neurite extension
was seen on PEGda. For this reason, PEGda would provide an excellent material for construction of
scaffolds that could be used for tissue engineering purposes.
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Chapter 4: Implantable Poly(ethylene glycol) Nerve Conduits Built by
Stereolithography for Peripheral Nerve Regeneration In Vivo
4.1

INTRODUCTION
Peripheral nerve injuries can occur as a result of automobile accidents, work accidents, falls,

athletic injuries, etc. They are a significant source of morbidity in trauma patients. Recent technology
has allowed for many advances in the repair of nerve injuries; two forms being direct repair and
autograft repair [10]. Neurorrhaphy, a type of direct repair, consists of direct surgical reconnection of
the proximal and distal nerve ends [See Figure 1.4 (A)]. Such repair can only be performed when the
defect is less than 5 mm [11]. Autograft repair, on the other hand, uses a nerve graft taken from a donor
site [10]. Autografts are more likely to be biocompatible than synthetic materials and they therefore, the
current standard of care for peripheral nerve injuries too large to be treated by direct repair. However,
there are several limitations to autograft repair including donor site morbidity and limited supply of
donor tissue [11]. Such deficiencies in direct and autograft repair have led researchers to look for other
methods to treat peripheral nerve injuries. A nerve guidance conduit can provide a promising alternative
to the previously mentioned methods [10, 11, 13].
Several biomaterials, both natural and synthetic, have been studied for construction of nerve
guidance conduits. Only a few have been approved by the US Food and Drug Administration (FDA) for
use in peripheral nerve repair: type I collagen, polyglycolic acid (PGA), poly(α-lactide-ε-caprolactone)
(PCL), porcine small intestine submucosa (SIS), and polyvinyl alcohol (PVA) [16]. Of these materials,
results obtained with PCL conduits more closely resemble those obtained with autografts [54]. Animal
studies are an essential part of the testing process of medical devices intended for human use. This is
because it is necessary to see how the devices interact with and react to the physiological environment.
Animal studies are also a critical part of the FDA’s application process. The FDA will not allow a
product to go to human trials until it has been proven through animal studies that the product does not
harm the organism.
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4.1.2

Objective
A study was conducted to assess the ability of nerve guidance conduits in promoting nerve

regeneration in vivo. A rat sciatic nerve injury model was used. Stereolithography (SL) was used to
build both, single and multi-lumen, conduits out of Poly(ethylene glycol) diacrylate (PEGda) to see
which type of conduit would better serve axon regrowth following injury.
4.2

MATERIALS AND METHODS

4.2.1

PEGda Solution Preparation
A solution of commercially available 3.4 kDa PEGda (Laysan Bio Inc., Arab, AL) was prepared

at a 30 wt% concentration. Irgacure-2959 (I-2959, Ciba Specialty Chemicals, Tarrytown, NY) was used
as a photoinitiator at 0.5 wt% concentration.

An RGDS-PEG conjugate was synthesized via a

previously outlined process [24] and added to the PEGda solution at 25 mg/mL.
4.2.2

Conduit Fabrication
The conduits were designed using SolidWorksTM software. With the material’s hydrophilic

properties in mind, the NCs were designed so they would reach a size appropriate to the animal model at
the equilibrium swollen state. The lumens were designed so that both single and multi-lumen conduits
would have the same cross-sectional area available for regeneration, 1.45 mm2 [See Figure 4.1]. The SL
equipment used for conduit fabrication was a 3D Systems® model 250/50 (3D Systems, Valencia, CA).
Conduits were built in batches of four using a laser scan speed of 8.085 in/s at a laser power of
approximately 19 mW. They were rinsed with deionized water to remove any unreacted PEGda and
photoinitiator and left to swell overnight. They were then lyophilized at -55°C using a freeze-dry
system (FreeZone 6, Labconco Corp., Kansas City, MO) and sterilized via low-temperature hydrogen
peroxide gas plasma (STERRAD® 100S, Advanced Sterilization Products, Irvine, CA).
4.2.3

Conduit Implantation
Eight Sprague Dawley rats were used for this procedure. Four were randomly chosen to receive

single-lumen conduits while the others were chosen to receive multi-lumen conduits.

Ketamine and

xylazine were used as anesthetics. The sciatic nerve of one leg was sharply transected while the
contralateral sciatic nerve was preserved as a control. The conduits were reconstituted in saline and the
nerve ends were sutured into the cap portion on each end. A 10 mm gap was left between nerve ends
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but no segments of nerve were removed. The animals were fed sterilized standard rat chow and water
ad libitum and were housed individually. The rats were sacrificed with carbon dioxide after 5 weeks and
the sciatic nerves and conduits were harvested.

The contralateral healthy sciatic nerve was also

harvested as a control. Surgeries were conducted at the University of California, Irvine and approved by
the University of California, Irvine Institutional Animal Care and Use Committee (IACUC) (protocol
can be seen in Appendix 3). They were performed in accordance with guidelines from the Association
for Assessment and Accreditation of Laboratory and Animal Care (AAALAC) and the National

Outer Diameter = 3.97mm

Inner Length = 10.41mm

Outer Length = 16.09mm

Institutes of Health (NIH).

Lumen Diameter = 1.36mm

Inner Diameter = 2.62mm

(B)
Outer Diameter = 3.97mm

Inner Length = 10.41mm

Outer Length = 16.09mm

(A)

Lumen Diameter = 0.51mm

Inner Diameter = 2.62mm

(C)

(D)

Figure 4.1: Conduit dimensions after being reconstituted; (A) Side view of single-lumen conduit; (B)
Top view of single-lumen conduit; (C) Side view of multi-lumen conduit; (D) Top view of multi-lumen
conduit
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4.2.4

Histomorphological Analysis
The resected nerves were fixed with a 3% glutaraldehyde solution and embedded in epoxy resin.

They were then stained with toluidine blue. It was decided to analyze the conduits at the proximal,
middle, and distal sections. Therefore, 3 slices were taken about 2 mm from the proximal section of the
nerve, 3 slices from the middle section, and 3 slices about 2 mm away from the distal section. From the
control samples, 3 slices were taken from the middle section only. An inverted microscope (Leica
DMIRB, Leica Microsystems, Germany) was used to digitize images with a charge-coupled device
camera (Retiga 2000S Fast 1394, QImaging Corp., Canada). High magnification (400x) images were
taken per slice for manual analysis. This included counting and measuring the number of small fibers
(axon < 6

m), number of large fibers (axon > 6

m), fiber diameter, axon diameter, and myelin

thickness. From these, g-ratio (axon diameter divided by fiber diameter) and the ratio of myelin
thickness to axon diameter were derived. Statistical differences between groups were analyzed using
analysis of variance (ANOVA). A two-sample t-test was used to compare results of single-lumen
samples. Equal variances were assumed and a p value lower than 0.05 was considered statistically
significant. Data are presented as mean

standard deviation. Figure 4.2 shows a schematic of a

myelinated axon illustrating how the measurements were taken.

Fiber Diameter

Myelin Thickness

Axon Diameter

Figure 4.2: Schematic of a myelinated axon showing how measurements were taken.
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4.3

RESULTS

4.3.1

Single-Lumen Conduits
In 2 of the 4 single-lumen conduits that were implanted, the conduit material was no longer

present at harvest. One conduit remained intact and regenerated tissue was visible within the lumen.
The last of the 4 conduits was surrounded by a large amount of tissue, possibly a neuroma. Images of
the single-lumen conduits during the harvest surgery can be seen in Figure 4.3.

Control
Sciatic Nerve

Conduit
Remains

Regenerated
Sciatic Nerve

(A)

(B)

Figure 4.3: Resection of single-lumen samples after 5 week period; (A) Control sciatic nerve on
opposite leg; (B) Implanted single-lumen conduit, sample was absorbed but some remains were still
present
From histological examination, 3 of the 4 rats given single-lumen conduits showed partial
regeneration. The tissue surrounding the remaining sample was a neuroma. Therefore, it was not
possible to analyze this sample. Figure 4.4 shows some of the high magnification (400x) images
obtained. The control (A) shows consistency and symmetry in axon diameter and myelin thickness.
The proximal section (B) resembles the control the most. However, small axons appear to be more
abundant. The middle section (C) is an example of the unrestrained growth nature of nerves. This
results in the presence of both transverse and longitudinal fibers within the same section. Finally, the
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distal section (D) shows many Schwann cell nuclei (illustrated by red circles). An increase in Schwann
cells is a common occurrence in regenerating fibers [55].

(A)

(B)

(C)

(D)

Figure 4.4: Cross-sectional images of single-lumen samples; (A) Control; (B) Proximal section; (C)
Middle section; (D) Distal section
As illustrated in Figure 4.5, the controls consistently showed a greater number of axons than the
test samples. The middle portion of the controls averaged 6080 ± 628 fibers/mm2 while the middle
section of the samples averaged 4490 ± 2810 fibers/mm2. There was also a visible decrease in total
number of fibers between the proximal and distal sections of the single-lumen samples. This was
expected being that regenerating fibers sprout from the proximal stump of an injured nerve. There was
no statistically significant difference between the samples and the control. Fiber composition was
analyzed by classifying any fibers with an axon diameter smaller than 6 µm as “small fibers.” Fibers
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with axons larger than 6 µm were labeled “large fibers.” The test samples all demonstrated a greater
number of small axons, averaging 71.3

44.0% with the highest proportion seen in the distal section.

On the other hand, in the control group, small fibers represented only 41.9 ± 6.6%.

Figure 4.5: Large, small, and total number of fibers per mm2 in single-lumen samples; #: Difference
from the control is statistically significant, p<0.05
The total fiber diameter can be seen in Figure 4.6. It was calculated as the sum of axon diameter
and myelin thickness [See Figure 4.2]. In this case, the average myelin thickness was doubled to
represent the total thickness across both sides of the axon. The control showed a larger fiber diameter
than the test samples. However, the decrease was not consistent as the middle section had a larger fiber
diameter than the proximal section. This was due to a larger axon diameter. All differences from the
control were statistically significant. Myelin thickness too was lower in the test samples as compared to
the control. This is illustrated in Figure 4.7. Myelination thinned from the proximal to distal direction.
In the middle, myelin thickness was 2.53

0.87 m compared to 3.00

1.02 m in the control. This is

a decrease of 15.8%. The difference between all of the sections and the corresponding controls was
statistically significant.
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Figure 4.6: Average fiber diameter according to axon diameter and myelin thickness, average myelin
thickness was doubled to represent total thickness across both sides of the axon. #: All differences from
the control are statistically significant, p<0.05

Figure 4.7: Average myelin thickness separated between small and large nerve fibers. #: All
differences from the control are statistically significant, p<0.05
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Table 4.1 represents the myelin thickness to axon diameter ratio. It too was smaller in the test
samples than the control and showed a trend of decrease from proximal to distal. The g-ratio, a ratio of
axon diameter to total fiber diameter, was actually greater in the middle and distal sections when
compared to the control group. This can be seen in Table 4.2.

Table 4.1: Ratio of Myelin Thickness to Axon Diameter

Control
Proximal
Middle
Distal

Large Fibers
Average
Ratio
0.77
0.67
0.49
0.35

Standard
Deviation
0.14
0.18
0.13
0.01

Small Fibers
Average
Ratio
1.07
1.01
0.86
0.75

Standard
Deviation
0.13
0.16
0.12
0.04

Table 4.2: g-Ratio

Control
Proximal
Middle
Distal

4.3.2

Average
Ratio
0.54
0.45
0.63
0.63

Standard
Deviation
0.05
0.05
0.08
0.08

Multi-Lumen Conduits
Upon harvest, 2 of the multi-lumen conduits remained intact. Regenerated tissue was visible

within some of the lumens. The other 2 conduits appeared to be encapsulated in fibrous tissue. Images
of the multi-lumen conduits during the harvest surgery can be seen in Figure 4.8. Histolomorphological
examination revealed severe paucity of axon regrowth within the multi-lumen conduits.

Partial

regeneration was seen in only 1 of 4 conduits. Therefore, it was not possible to calculate the various
parameters calculated for single-lumen conduits. Examples of images obtained from the multi-lumen
group are seen in Figure 4.9. Image (A) shows a low magnification (25x) image of the middle portion
of a test sample. The lumens are visible and regenerated tissue is present in 6 of the 7 lumens. Image
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(B) is a high magnification (400x) image of a distal section. Some axonal and myelin formation is
present. However, there is little consistency in size and shape.

Nerve end

Visible
regenerated
tissue

Implanted
conduit
Nerve end

Noticeable
conduit layers

(A)

(B)

Figure 4.8: Resection of multi-lumen samples after 5 week period; (A) Nerve sutured to NGC; (B)
Resected NGC in preservation fluid.

(A)

(B)

Figure 4.9: Cross-sectional images of multi-lumen samples; (A) Low magnification image of
middle section; (B) High magnification image of distal section
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4.4

DISCUSSION
The purpose of this study was to explore the use of single and multi-lumen conduits as an

alternative to the current nerve repair techniques. It also attempted to study the axonal growth and
myelination at proximal, middle, and distal segments of a sciatic nerve injury. Two of the 4 singlelumen conduits that were implanted were no longer present upon harvest. Despite the fact that no
degradation sequences were used in this PEG solution, others have shown that PEG-RGDS is
susceptible to oxidative degradation. Lynn et al. demonstrated that PEG-RGDS can degrade faster than
PEG-only solutions [56]. This is likely due to the negatively-charged Arginine in RGDS, which has a
higher equilibrium swelling ratio, leading to faster degradation times. Histomorphological analysis
revealed partial regeneration in 3 of 4 single-lumen conduits. It also revealed that morphology within
single-lumen conduits was approaching that found in the controls. There were a greater percentage of
fibers of small diameter within the single-lumen conduits than in the controls, indicating the presence of
new, regenerating axons. Previous work by Sanders et al. showed there is a decrease in axon diameter
and an increase in myelin thickness commonly seen in regenerating axons [57]. The axons in this study
did, in fact, present a decrease in axon diameter within single-lumen samples. However, there was not a
similar increase in myelin thickness. This can also be seen in the myelin thickness to axon diameter
ratio. When a decrease in axon diameter and an increase in myelin thickness are present, a higher value
would be expected in regenerating axons versus the controls. In this case, the ratio values were lower
when compared to the controls. The main difference between this study and that conducted by Sander et
al. is that their samples were analyzed after 60 days while these were harvested after 35 days. It may
have been too early to allow the expected increase in myelin thickness to take place. Another study also
saw peripheral nerve regeneration occurring at approximately the 2 month time point [58]. The g-ratio,
or the ratio of axon diameter to fiber diameter, was calculated as it is used to assess nerve maturity. For
a nerve to have optimum conduction velocity, a g-ratio of about 0.50, as seen in the controls, is
necessary. The g-ratio of the middle and distal sections in single-lumen samples was slightly higher
(~0.60), implying that considerable myelination had still not taken place.
The purpose of building multi-lumen conduits was increased the surface area available for
Schwann cell adherence and delivery of growth stimulating proteins without decreased cross-sectional
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area. Hadlock et al. used poly(lactic-co-glycolic acid) (PLGA) conduits to demonstrate improved
regeneration in multi-lumen conduits and proposed that additional lumens lead to better regeneration
[59]. On the hand, De Ruiter et al. found no difference amongst single- and multi-lumen PLGA
conduits even tissue regenerated tissue was seen in only 3 of 7 lumens. It should also be noted that their
conduits differed in cross-sectional area (0.8 mm2 in multi-lumen conduits and 2 mm2 in single-lumen
conduits) while those of the present work did not (1.45 mm2 for both types). PEGda and PLGA also
differ in hydrophilicity, stiffness, and degradability. These are physical properties that can have an
influence on an organism’s response to a material. Regenerated tissue was visible within 2 of the 4
multi-lumen samples, as was seen in the cross-sectional view where regeneration was present in 6 of the
7 lumens [Figure 4.8 (A)]. There may have also been some regenerated tissue within the other 2
conduits that were encapsulated in fibrous tissue. However, the multi-lumen architecture made these
more difficult to section and stain, complicating analysis. The PEGda conduits used for this research
were not degradable nor contained any growth factors, other than a cell adhesion peptide. Both are
features that can significantly affect the biological response to multi-lumen conduits; therefore,
improving nerve regeneration.
Several factors made this analysis difficult to conduct. Due to an unrestrained growth nature of
nerves, some sections had fibers cut longitudinally rather than transversely, affecting axon counts and
diameters. Neuroma formation on 1 of the single-lumen conduits prevented regeneration within that
conduit.

There were also complications from sectioning and staining of multi-lumen samples.

Therefore, nerve regeneration was visible in only 1 sample within the multi-lumen group. It was not
possible to calculate the various histomorphological parameters of the nerve fibers in this group. As a
result, only parameters in the single-lumen and control groups were compared. This, in conjunction
with low sample size and short experimental duration, limited the ability to draw conclusions with
statistical significance. Future studies, using other methods for fixation, staining, and sectioning of
tissue, may provide better histomorphological results. These should also use larger sample sizes and
longer time points. Functional and behavioral investigation would better characterize the therapeutic
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potential of these conduits such as gastrocnemius and soleus muscle weight, sciatic functional index, and
extensor postural thrust.
4.5

CONCLUSIONS
Peripheral nerve injuries are a significant issue amongst trauma patients.

Nerve guidance

conduits provide a potential solution. Although some conduits are available on the market today, they
can only be utilized for bridging small gaps and do not work as well as autografts. Conduits built via SL
may provide a more successful alternative to the current methods. This study demonstrates the ability of
single-lumen PEGda conduits built using SL to facilitate nerve regeneration.

Initially, it was

hypothesized that multi-lumen conduits would outperform their single-lumen counterparts due to the
fact that they provide a greater surface area for regeneration. However, better axon regrowth was seen
in single-lumen conduits.

This does not suggest multi-lumen conduits are inefficient in aiding

regeneration. It simply means that other methods of tissue preparation for microscopic analysis should
be explored.
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Chapter 5: Using a Small Beam Stereolithography System for Increased Surface
Area in Nerve Guidance Conduits
5.1

INTRODUCTION

5.1.1

Background
One of the topics being studied in the field of nerve tissue engineering is whether an increase in

the surface area of a conduit will result in improved regeneration. This is because it is believed that
increasing surface area increases the area for Schwann cell adherence as well as the area for delivery of
growth stimulating proteins [59]. Attachment is necessary to Schwann cell survival and proliferation.
When axons are not yet present, the cells need a surface to adhere to [60]. Several techniques for
increasing surface area within nerve guidance conduits have been investigated including, electrospinning
and polymer foam processing [59, 61, 62]. Similarly, stereolithography (SL) can be used to achieve
these results. In vivo tests performed in Chapter 4 of this thesis focused on studying conduits which
were designed to have either 1 large lumen (530 µm diameter) or 7 medium lumens (400 µm diameter).
The SL machine used to build those conduits (SLA 250/50) used a HeCd UV laser with a beam diameter
of 250 µm. This laser limits the line widths and wall thickness to 250 µm; which in turn, limits the
amount of lumens that can be incorporated into a conduit. By reducing the laser diameter, more lumens
of smaller size can be incorporated into conduits, increasing the surface area available for cell
attachment.
5.1.2

HeCd Laser Specifications
The HeCd laser found in an SLA 250/40 has a wavelength of 325 nm and a beam diameter of

1.40 mm. The U-shaped structure of the laser can be seen in Figure 5.1. A glass plasma discharge tube
is filled with He gas and is connected to a reservoir containing solid Cd. The reservoir is attached to a
heating element which heats the Cd to vaporize. It then mixes with the He gas. Two electrodes,
attached to the ends of the U-shaped tube, provide a high voltage potential creating an electric field
across the tube. This field ionizes the He-Cd gas mixture, emitting photons as the result of excessive
energy. A percentage of these photons are used by the SL system in the photopolymerization process.
The rest of the photons are resonated back into the tube by two parallel mirrors, located on either side of
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the tube, and collide with excited Cd atoms. This causes the release of another photon. The process is
repeated creating photons of equal wavelength, phase, and traveling direction which are bounced back
and forth between the mirrors. This is how a constant laser beam is produced [63].

Figure 5.1: Structure of the HeCd Laser [64]

As mentioned in Chapter 1, the critical exposure (EC) and penetration depth (DP) are modifiable
parameters on an SL system.

In addition to these, another parameter was analyzed, line width

compensation. Line width compensation is intended to compensate for the diameter of the laser and is
typically half of the laser beam diameter [65]. For example, the original laser diameter on an SLA
250/40 is 250 µm. As a result, the default line width compensation is .005 in (125 µm). Figure 5.2
illustrates this concept. The laser beam diameter can cause a slight increase in the dimensions of the
design. Line width compensation prevents this from happening so parts can have accurate dimensions.
It is a value that can be changed on the Build Style of the design in 3D Lightyear, prior to importing the
file into the SL system.
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Laser Beam
Laser Path

Design
Figure 5.2 Line width compensation
5.1.3

Objective
For this research, a commercial SLA 250/40 (3D Systems, Rock Hill, SC) was retrofitted inside a

laminar flow hood. This action served two objectives: to produce a laser beam of smaller diameter than
that found in a commercial SL system and to design an aseptic SL system in which clean, particulatefree scaffolds could be built. The laser diameter was reduced by modifying the location of the optics as
well as elevating the build stage and decrease the distance between the stage and the scanning mirror
system. A reduction in diameter should improve microfabrication capabilities by allowing construction
of smaller more complex features. It should also allow for construction of conduits with a greater
surface area for cell attachment while not sacrificing the cross-sectional area through which nerves can
regenerate.
5.2

MATERIALS AND METHODS

5.2.1

SL System Modification
The modification of the SL system was performed by Espalin et al. and can be seen in Figure 5.3

(A). To do this, they determined at which stage height and optical configuration the smallest beam
diameter could be achieved. As a beam of light travels, it spreads. Therefore, the beam is smaller
closest to the light source. A commercial SLA 250/40 already uses a computer controlled elevator to
move the stage vertically. However, the maximum height reached by the elevator was insufficient.
Therefore, adjustable metal rods were used to place a secondary, smaller stage closer to the optical
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window [See Figure 5.3 (B)]. Four rods were used in total, 2 for the stage and 1 for each of the beam
aligning sensors. By fastening the rods directly onto the original stage, the secondary stage could still be
controlled by movement of the elevator. An optical train was placed on the roof of the laminar flow
hood to which the lenses and mirrors could be attached. The components were placed on the train in a
way that they could slide back and forth along the rails, allowing for testing of the beam diameter at
several distances from each other. Using MATLAB (MathWorks, Natwick, MA), a Cooke triplet
optical system was chosen for placement of the lenses. This system uses a convex-concave-convex lens
configuration with symmetrical spacing between the 3 components.

Five mirrors were placed

throughout to guide the beam toward the computer controlled optical scanning mirror directly above the
stage. Fine tuners on the lenses and mirrors were used to ensure the beam maintained a circular shape
[64]. In the end, the laser beam diameter was reduced to as small as 139.3 ± 14.5 µm. The Cooke triplet
set-up can be seen in Figure 5.4.
5.2.2

PEGda Solution Preparation
For these tests, a solution of commercially available 3.4 kDa PEGda (Laysan Bio Inc., Arab, AL)

was prepared at a 30 wt% concentration. Irgacure-2959 (Ciba Specialty Chemicals, Tarrytown, NY)
was used as a photoinitiator at 0.5 wt% concentration. Sterile 1X phosphate buffered saline (PBS) was
used as the solvent. All solutions were prepared in a biosafety cabinet (Purifier Class II, Labconco,
Kansas City, MO).
5.2.3

SL System Calibration
The first step in attempting to build parts using the retrofitted SL system was calibration. Initial

attempts at building yielded samples approximately one quarter the size of the CAD file. A calibration
file provided by 3D Systems (Rock Hill, SC) was used to calibrate the system. For this, a simple 25.4
mm x 25.4 mm (1 in x 1 in) square design was built to acquire x and y dimensions. The dimensions
were saved into the calibration file and the file was imported into the retrofitted SL system’s control
center. The square was re-built to confirm success of the calibration. All samples were analyzed using a
Leica MZ16 Stereomicroscope (Leica Microsystems, Germany). Images were taken with a chargecoupled device camera (Retiga 2000S Fast 1394, QImaging Corp., Canada).
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Figure 5.3: (A) Retrofitted SL system, (B) View of elevated build stage
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Figure 5.4: Cooke triplet optical assembly of lenses and mirrors; red line indicates laser path. Adapted
from [63]
Various conduit configurations were designed using SolidworksTM. All conduit designs had an
outer diameter of 2.94 mm and an inner diameter of 1.97 mm. A single-lumen conduit was designed to
have a 530 µm lumen. A 7-lumen conduit with lumen diameter of 400 µm was also made. Finally,
three more conduits were designed to have 14, 16, and 18 lumens of a 240 µm diameter. These CAD
files can be seen in Figure 5.5. The 7-lumen design was chosen to determine the best build parameters
to use with this laser. This was done by building a single layer of a 7-lumen sample at various DP and
line width compensation values. All of the samples were built with an EC value of 12 mJ/cm2 as it had
proven to work well in the past. Once the best parameters were chosen, single layer samples of the other
3 designs were built to verify dimensions. Two-layer samples were also built to note if the various
lumens remained open when a new layer was built above an existing one. Partial conduits of each were
built consisting of 4 lumenal layers and 2 cap layers. Finally, a whole layer 14-lumen conduit was built
with 2 cap portions.
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7-Lumen

14-Lumen

16-Lumen

18-Lumen

Top View

Side View

Single-Lumen

Lumen diameter: Lumen diameter: Lumen diameter: Lumen diameter: Lumen diameter:
400 µm
240 µm
240 µm
240 µm
1120 µm
Figure 5.5: Side and top views of conduit CAD models. All had the following dimensions: inner
diameter = 1.97 mm, outer diameter = 2.94 mm, total length = 16 mm, length of lumen portion = 10 mm
5.2.5

Comparing Cross-sectional and Surface Areas
Cross-sectional and surface areas of the various lumen diameters were calculated for both the

CAD dimensions and swollen dimensions. A length of 10 mm was used for the lumen portion of the
conduits. However, it should be noted that conduit length can be adapted to fit the length of the injury.
The following equation was used to calculate cross-sectional area:
A = лr2n

(5.2 - 1)

where
A is cross-sectional area,
r is radius of the lumens,
n is number of lumens.
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Surface area was calculated using the following equation:
SA = 2лrhn

(5.2 - 2)

where
SA is surface area,
r is radius of the lumens,
h is height of the lumen portion of conduit,
n is number of lumens.
To calculate cross-sectional and surface areas when the sample is in a swollen state, the Dimensional
Swelling Factor was used. The values for this material (PEGda 3.4 kDa at 30 wt%) were previously
calculated by Arcaute et al.: 1.18 ± 0.008 for conduit length and 1.21 ± 0.039 for lumen diameter [27].
The following equation was used:
Dimensional Swelling Factor = Swollen Dimension
Design Dimension
5.3

(5.2 - 3) [27]

RESULTS
The results of the various build parameters that were tested can be seen in Figure 5.6. As

previously mentioned, all samples were built with an EC value of 12 mJ/cm2. For Sample A, a DP value
of 8 mil was used which yielded a speed of 2.994 in/s. This sample used a line width compensation of
0.005 in. The diameter of the lumens (~509 µm) was too large. Therefore, for Sample B, the line width
compensation was decreased by half, at .0025 in. Without modifying EC or DP values, the speed
decreased slightly to 2.837 in/s. The diameter of the lumens was better than the previous (~397 µm).
However, the outer edges on this sample were rather rough. On the bottom surface of the sample, the
lumens did not have a nice circular shape. In Sample C the laser speed was reduced to 2.343 in/s by
reducing the DP to 7 mil. This made the lumens slightly smaller (~390 µm) but they had a more
consistent round shape on the top and bottom surfaces. The edges on this sample were smoother than
the previous two. Finally, in Sample D the DP was lowered to 6 mil, lowering the speed to 1.739 in/s.
Although the surface finish was smooth, the decrease in speed caused a decrease in the size of the
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lumens (~361 µm). Therefore, the parameters set in Sample C were considered the best option for
construction of additional samples.

Build Parameters

Outer Diameter

Lumen Diameter

EC = 12 mJ/cm2
DP = 8 mil
(A)

VS = 2.994 in/s
LWC = 0.005 in
EC = 12 mJ/cm2
DP = 8 mil

(B)

VS = 2.837 in/s
LWC = 0.0025 in
EC = 12 mJ/cm2
DP = 7 mil

(C)

VS = 2.343 in/s
LWC = 0.0025 in
EC = 12 mJ/cm2
DP = 6 mil

(D)

VS = 1.739 in/s
LWC = 0.0025 in

Figure 5.6: Testing build parameters on a 7-lumen sample; EC = critical exposure, DP = penetration
depth, VS = laser scan speed, LWC = line width compensation
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Successful construction of 14, 16, and 18-lumen samples was achieved. The best results of these
can be seen in Figure 5.7. Initially only a single layer of each design was built to ensure proper lumen
shape and dimensions. The 2-layer samples showed good attachment between the layers. The bottom
layer (first layer built) became thinner once the top layer was added. There was some decrease in
diameter by the lumens when compared to the single layer samples. However, both top and side views
show the lumens remained open. Like the single layer samples, the lumens have a uniform circular
shape. The 6 layer samples (4 lumen layers + 2 cap layers) also showed consistent shape and diameter
of the lumens. The lumens still remained open. The 14-lumen sample was built with the cap portion
first and the lumen portion on top. However, like the 2-layer sample the first layer decreases in size
with addition of a second layer. It was decided to build the 16 and 18-lumen samples with the lumen
portion first and the cap portion on top. This way, the length of the cap portion would not be affected.
The surface finish was somewhat rough as there was clear definition amongst the individual layers. The
14-lumen design was chosen for construction of a full conduit. Four layers were used for the bottom
cap, 8 for the lumen section, and 3 for the top cap. This sample can be seen in Figure 5.8. Image (A)
shows how the sample looked immediately after fabrication. Unlike the 6 layer samples previously
built, this sample had a cleaner surface finish. It also appeared more symmetrical. Suture thread was
used to show the lumens remained open despite the layers being built on top of one another [See Figure
5.8 (B)]. Although the single-lumen conduit was designed, it was not built. This was decided because
the large lumen can be built with a commercial SL system. The CAD file, though, did help in
calculating surface and cross-sectional areas.
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Figure 5.7: Top and side views of 14, 16, and 18-lumen samples

Bottom Cap

Lumen Portion
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(B)
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Figure 5.8: Full size 14-lumen conduit; (A) As fabricated; (B) Suture thread used to show open lumens
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Using the equation for Dimensional Swelling Factor (5.2-3), swollen values were obtained for
the length of the lumen portion of the conduit as well as the lumen diameters. Both, swollen and asfabricated, dimensions can be seen in Table 5.1. These were used to calculate the cross-sectional and
lumenal surface areas. The dimensions of the single and 7-lumen conduits were previously calculated so
they would both have the same cross-sectional area. In this case, the cross-sectional area is larger for
both than it is for the samples with the smallest lumen size. However, the 18-lumen sample has crosssectional areas of 0.81 mm2 and 1.19 mm2 for as-fabricated and swollen dimensions, respectively.
These differ by only 0.07 mm2 and 0.1 mm2 from the single and 7-lumen samples. On the other hand,
the lumenal surface area increases as the number of lumens increases. The surface area found in 18lumen samples was greater than 4 times that found in single-lumen samples. This is seen in both asfabricated and swollen conduit dimensions.
Table 5.1: As-Fabricated and Swollen Conduit Dimensions
As-Fabricated
Length of
Lumen
Portion
Lumen
Diameter

Swollen

Singlelumen

7-lumen

14, 16, 18lumen

Singlelumen

7-lumen

14, 16, 18lumen

10 mm

10 mm

10 mm

11.8 mm

11.8 mm

11.8 mm

1.06 mm

0.40 mm

0.24 mm

1.28 mm

0.484 mm

0.29 mm

Table 5.2: Area Comparisons

Single-Lumen
7-Lumen
14-Lumen
16-Lumen
18-Lumen

As-Fabricated
Cross-Sectional
Lumenal
Area
Surface Area
0.88 mm2
33.30 mm2
0.88 mm2
87.96 mm2
2
0.63 mm
105.56 mm2
0.72 mm2
120.64 mm2
2
0.81 mm
135.72 mm2
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Swollen
Cross-Sectional
Lumenal
Area
Surface Area
1.29 mm2
47.45 mm2
1.29 mm2
125.60 mm2
2
0.92 mm
150.51 mm2
1.06 mm2
172.01 mm2
2
1.19 mm
193.51 mm2

5.4

DISCUSSION
Various methods have been studied for increased surface area within nerve guidance conduits.

This is because it is believed that increasing surface area increases the area for Schwann cell adherence
as well as the area for delivery of growth stimulating proteins [59]. One method that has been studied for
construction of conduits is electrospinning [61, 62]. Electrospinning is a technique that creates fibrous
scaffolds when high voltage is applied to a photopolymer solution [66]. The fibrous nature of these
scaffolds is of interest to researchers because it provides a large surface area for regeneration. For
example, Chew et al. used electrospinning to build a conduit made from a caprolactone and ethyl
ethylene phosphate (PCLEEP) copolymer. The electrospun conduits outperformed non-electrospun
control conduits by 50% [62]. Another technique that has been studied to increase conduit surface area
is polymer foam processing. This is done by injecting a polymer solution under low pressure into a
stainless steel mold and cooling the solution. Hadlock et al. used stainless steel wire molds to create
conduits of over 100 lumens. Cross-sectional images revealed neural tissue regeneration that was
comparable to autograft controls [59].
Similar results can be obtained using SL. In vivo tests performed in Chapter 4 of this thesis
focused on studying conduits which were designed to have either 1 large lumen (530 µm diameter) or 7
medium lumens (400 µm diameter). The SL machine used to build those conduits (SLA 250/50) used a
HeCd UV laser with a beam diameter of 250 µm. This laser limits the line widths and wall thickness to
250 µm; which in turn, limits the amount of lumens that can be incorporated into a conduit. By reducing
the laser diameter, more lumens of smaller size can be incorporated into conduits, increasing the surface
area available for cell attachment.
Construction of a retrofitted SL system with a reduced laser beam diameter, allowed for
construction of conduits with increased number of lumens. Testing various parameters using a 7-lumen
design was necessary to determine EC, DP, laser scan speed, and line with compensation values to
achieve the best samples. By reducing the lumen diameter from 400 µm to 240 µm, it was possible to
incorporate over twice the number of lumens as that found in a 7-lumen conduit.

Successful

construction of 1, 2, and 6 layer samples was achieved to verify lumen diameter and shape consistency.
Building a full 14-lumen conduit proved that lumens remain open despite layer stacking. Although
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cross-sectional area is decreased the difference in samples with a high number of lumens is comparable
to that of larger lumens. On the other hand, surface area is significantly increased as lumen diameter is
reduced and number of lumens is increased.
5.5

CONCLUSIONS
Researchers in nerve regeneration methods believe that increasing surface area on a conduit

increases the surface available for cell attachment and delivery and nerve stimulating proteins.
Construction of a retrofitted SL system with a reduced laser beam diameter, allowed for construction of
conduits with increased number of lumens. Testing various parameters using a 7-lumen design was
necessary to determine EC, DP, laser scan speed, and line with compensation values to achieve the best
samples. By reducing the lumen diameter from 400 µm to 240 µm, it was possible to incorporate over
twice the number of lumens as that found in a 7-lumen conduit. Successful construction of 1, 2, and 6
layer samples was achieved to verify lumen diameter and shape consistency. Building a full 14-lumen
conduit proved that lumens remain open despite layer stacking.

Although cross-sectional area is

decreased, the difference in samples with a high number of lumens is comparable to that of larger
lumens. On the other hand, surface area is significantly increased as lumen diameter is reduced and
number of lumens is increased.
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Appendix 1: Glossary of Abbreviations
3D

Three-dimensional

ACRL-PEG-NHS

Acryloyl-PEG-N-hydroxysuccinimide

Anti-NGF mAb

Monoclonal antibody

Anti-NGF pAb

Polyclonal antibody

Anti-Rat IgG, HRP Conjugate

Antibody conjugated to horseradish peroxidase

BSA

Bovine Serum Albumin

CAD

Computer-aided design

CNS

Central nervous system

DP

Penetration depth

EC

Critical exposure

ELISA

Enzyme-linked immunosorbent assay

GPS

Glutamine-penicillin-streptomycin

IKVAV

Isoleucine-Lysine-Valine-Alanine-Valine

NGF

Nerve growth factor

PBS

Phosphate buffered saline

PC-12

Rat pheochromocytoma cell line

PCL

Poly(α-lactide-ε-caprolactone)

PCLEEP

Caprolactone and ethyl ethylene phosphate copolymer

PEG

Poly(ethylene glycol)

PEGda

Poly(ethylene glycol) diacrylate

PGA

Polyglycolic acid

PLGA

Poly(lactic-co-glycolic acid)

PNS

Peripheral nervous system

PPE

Poly(phosphoester)

P(PF-co-EG)

Poly(propylene fumarate-co-ethylene glycol)

PVA

Polyvinyl alcohol

RGDS

Arginine-Glycine-Aspartic acid-Serine

SIS

Porcine small intestine submucosa

SL

Stereolithography

UV

Ultraviolet

YIGSR

Tyrosine-Isoleucine-Glycine-Serine-Arginine
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Appendix 2: Calculations
Calculating solutes for a PEGda solution at 30 wt% concentration:
% by mass solute = mass of solute x 100%
mass of solution
Mass of PEGda = 1 g
Mass of PBS = x
Mass of I-2959 = y
To calculate Mass of PBS, starting with 1 g PEGda:
30% = 1 x 100%
1+x
0.3 (1+x) = 1
0.3 + 0.3x = 1
0.3x = 0.7
x = 0.7 = 2.33
0.3
Density of PBS = 1 g/mL
2.33 mL of PBS

To calculate Mass of I-2959:
0.5% =
y
x 100%
1+2.33+y
0.005 (3.33 + y) = y
0.01665 + 0.005y = y
0.01665 = 0.995y
y = 0.0167
0.0167 g of I-2959
Totals: 1 g PEGda
2.33 mL PBS
0.0167 g I-2959
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Calculating solutes for a PEGda solution at 20 wt% concentration:
% by mass solute = mass of solute x 100%
mass of solution
Mass of PEGda = 1 g
Mass of PBS = x
Mass of I-2959 = y
To calculate Mass of PBS, starting with 1 g PEGda:
20% = 1 x 100%
1+x
0.2 (1+x) = 1
0.2 + 0.2x = 1
0.2x = 0.8
x = 0.8 = 4
0.2
Density of PBS = 1 g/mL
4 mL of PBS

To calculate Mass of I-2959:
0.5% = y x 100%
1+4+y
0.005 (5+y) = y
0.025 + 0.005y = y
0.025 = 0.995y
y = 0.0167
0.0251 g of I-2959
Totals: 1 g PEGda
4 mL PBS
0.0251 g I-2959
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Calculating cross-sectional area of nerve guidance conduits, as-fabricated:
CA = лr2n
where
CA is cross-sectional area
r is radius of the lumens
n is number of lumens
1 Lumen:

r = 0.53 mm, n = 1
CA = л(0.53mm)2 x 1 = 0.88 mm2

7 Lumen:

r = 0.20 mm, n = 7
CA = л(0.2 mm)2 x 7 = 0.88 mm2

14 Lumen:

r = 0.12 mm, n = 14
CA = л(0.12 mm)2 x 14 = 0.63 mm2

16 Lumen:

r = 0.12 mm, n = 16
CA = л(0.12 mm)2 x 16 = 0.72 mm2

18 Lumen:

r = 0.12 mm, n = 18
CA = л(0.12 mm)2 x 18 = 0.81 mm2

Calculating cross-sectional area of nerve guidance conduits, swollen:
CA = лr2n
where
CA is cross-sectional area
r is radius of the lumens
n is number of lumens
1 Lumen:

r = 0.64 mm, n = 1
CA = л(0.64 mm)2 x 1 = 1.29 mm2

7 Lumen:

r = 0.242 mm, n = 7
CA = л(0.242 mm)2 x 7 = 1.29 mm2

14 Lumen:

r = 0.145 mm, n = 14
CA = л(0.145 mm)2 x 14 = 0.92 mm2

16 Lumen:

r = 0.145 mm, n = 16
CA = л(0.145 mm)2 x 16 = 1.06 mm2

18 Lumen:

r = 0.145 mm, n = 18
CA = л(0.145 mm)2 x 18 = 1.19 mm2
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Calculating surface area of nerve guidance conduits, as-fabricated:
SA = 2лrhn
where
SA is surface area
r is radius of the lumens
h is height of the lumen portion of conduit
n is number of lumens
1 Lumen:

r = 0.53 mm, h = 10 mm, n = 1
SA = 2л (0.53 mm) (10 mm) x 1 = 33.30 mm2

7 Lumen:

r = 0.20 mm, h = 10 mm, n = 7
SA = 2л (0.20 mm) (10 mm) x 7 = 87.96 mm2

14 Lumen:

r = 0.12 mm, h = 10 mm, n = 14
SA = 2л (0.12 mm) (10 mm) x 14 = 105.56 mm2

16 Lumen:

r = 0.12 mm, h = 10 mm, n = 16
SA = 2л (0.12 mm) (10 mm) x 16 = 120.64 mm2

18 Lumen:

r = 0.12 mm, h = 10 mm, n = 18
SA = 2л (0.12 mm) (10 mm) x 18 = 135.72 mm2

Calculating surface area of nerve guidance conduits, swollen:
SA = 2лrhn
where
SA is surface area
r is radius of the lumens
h is height of the lumen portion of conduit
n is number of lumens
1 Lumen:

r = 0.64 mm, h = 11.8 mm, n = 1
SA = 2л (0.64 mm) (11.8 mm) x 1 lumens = 47.45 mm2

7 Lumen:

r = 0.242 mm, h = 11.8 mm, n = 7
SA = 2л (0.242 mm) (11.8 mm) x 7 lumens = 125.60 mm2

14 Lumen:

r = 0.145 mm, h = 11.8 mm, n = 14
SA = 2л (0.145 mm) (11.8 mm) x 14 lumens = 150.51 mm2

16 Lumen:

r = 0.145 mm, h = 11.8 mm, n = 16
SA = 2л (0.145 mm) (11.8 mm) x 16 lumens = 172.01 mm2

18 Lumen:

r = 0.145 mm, h = 11.8 mm, n = 18
SA = 2л (0.145 mm) (11.8 mm) x 18 lumens = 193.51 mm2
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Appendix 3: UC Irvine's IACUC Protocol

PROTOCOL NARRATIVE
University of California, Irvine
Institutional Animal Care and Use Committee
Version: May 2007
IACUC#:____________________
For IACUC Office Use Only
Lead Researcher Name: Gregory R. D. Evans, M.D., F.A.C.S.
Title: Inducible Nerve Growth Factor Delivery for Peripheral Nerve Regeneration
Important: Save this form before filling it out.
Review of the Protocol Instructions is strongly recommended. Click on each section heading for a direct link to
the corresponding section of the application instructions.
SECTION 1: PROJECT OVERVIEW

Provide a non-technical, lay language summary of the proposed project that can be understood by
IACUC members with varied research backgrounds, non-scientists and community members.
Discuss the potential relevance (e.g., benefits) of findings to human or animal health, advancement of
knowledge, and/or the good of society. This summary should not exceed 250 words.
Notes:
x Avoid using scientific terminology, jargon or unexplained abbreviations; where use of such
language is unavoidable, provide definitions of all terms.
x Do not cut and paste from a grant application, journal article or abstract.

The ultimate goal of this proposal is to develop a clinically translatable tissue engineered strategy for
peripheral nerve repair and replacement that avoids the limitations associated with the current standard of
care, which is the use of autologous nerve transplants harvested from uninjured regions of the patient’s
body. Peripheral nerve injuries can result from mechanical, thermal, chemical, congenital or pathological
causes. To date surgical approaches for nerve repair are limited due to various reasons. The availability of
normal donor nerves from an uninjured body location for surgical nerve repair is limited, and it may be
associated with an increase in deformities, differences in structure and size and surgical complications such
as bleeding, infections and pain. Furthermore, the use of nerves from other human beings or even animals
for nerve replacement has shown poor outcomes. One possible alternative is the development of
engineered constructs to replace those elements necessary for regeneration of the injured nerve and
include a structural lead for the nerve growth to bridge the nerve gap, support cells, growth factors, and
substances that fill the space between the cells of the nerve. Despite advances and contributions in the field
of tissue engineering, results have failed to equal nerve regeneration realized when surgical repair was
done with a nerve from a different body location.
The objective of this proposal is to develop a strategy to deliver nerve growth factor (NGF) to improve
peripheral nerve regeneration. Nerve growth factor (NGF) is one of the most important regulatory
substances to stimulate nerve regeneration. Creating an inducible system which allows the production of
NGF to boost and stop would make peripheral nerve regeneration controllable.

SECTION 2: JUSTIFICATION FOR THE USE OF ANIMALS
A. Rationale for the Use of Animals

Federal regulations require that all investigators provide a narrative describing the rationale for using
animals, the appropriateness of the species and the methods and specific sources used to determine
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that alternatives (e.g. replacement, reduction, refinement) to the use of animals and to the procedures
have been considered.
Please answer all of the subsections below:

1.

Explain why animals are required for these studies, and why non-animal model replacements,
such as cell culture or computer modeling, cannot fully replace animals:

Animals are utilized to measure the efficacy of the NGF delivery system on peripheral nerve regeneration and
functional restoration.
In-vitro analysis is employed within this study to evaluate the early transfection efficacy. However, the
ultimate test of nerve proliferation is in-vivo analysis. This combines the complex process of axonal migration
and cell interaction. Nerve injury and a novel approach to nerve repair injury repair is proposed. An intact and
injured nerve responding in it's natural physiological milieu is essential in order to assess functional nerve
recovery. This can only be achieved using a live vertebrate animal model.

2.

Explain why the proposed species are the most appropriate:

The Nude rat is being chosen to eliminate immunologic reactions between the human NGF protein and the
HEK-293 cells. Further, the use of Nude rats better equates to the use of autografts when nerve is harvested
from donor animals and placed within a recipient's defect (isografts). Additionally, functional analysis,
electrical conduction studies and histochemical markers have been well-established for the Nude rat.
Although larger nerve gaps will entail the use of larger animals (i.e. rabbits), the nerve gaps within the rat will
prove adequate to determine the feasibility of this delivery system.

B. Alternatives to the Use of Animals

The United States Department of Agriculture (USDA) requires that you specify at least two sources or
databases used to determine that the model and methods described in this protocol do not:
x Unnecessarily duplicate previous experiments,
x Unnecessarily use animals, or
x Unjustifiably expose animals to potentially painful, uncomfortable or distressful procedures.
1. Database Searches
Indicate with an “X” in the bracket [
alternatives:

] which databases (at least 2) were used to search for

[ X ] National Agricultural Library (AGRICOLA)
[ ] BIOSIS Previews
[ ] CORDIS
[ ] CRISP
[ ] NORINA
[ ] TBASE
[ ] TOXLINE
[ ] Web of Science

[ ] AltWeb
[ ] CRIS
[ ] PsycINFO
[ X ] MEDLINE via PubMed

2. Date(s) the database search was performed:
Note: the search must be within the last 3 months
09/11/2009
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3. Years (e.g., 1985 to present) covered by the search:
1989 to present
4. Keywords used in the search:
- Peripheral nerve regeneration
- Nerve regeneration
- Sciatic nerve exposure
- Animal alternatives
- Computer-based nerve regeneration
- Nerve growth factor/NGF
- Regulation of growth factor/NGF
- Cell kill by HSV-TK
- Ponasterone A
Note: In general the more "keywords" you use the more specific your search will be; however, it is
possible to be so specific that nothing will be found. In that case you should reduce the number of
terms used. Click here for search tips.
5. If a consultant was used for considering alternatives, provide the following information:
[ X ] Not applicable – Two databases in #1 were the primary means for considering alternatives.
Expert consultant’s name:
Consultant’s qualifications/expertise:
Content of the consultation:
Date(s) of the consultation:

Type here
Type here
Type here
Type here

6. Narrative Description - Reduction, Refinement and Replacement
Discuss the results and findings of search—be specific. Describe the steps you have taken to
replace the use of animals with in vitro procedures, reduce the number of animals used, refine the
experimental design, and refine procedural techniques. If similar experiments are found, describe
the aspects of your research project that are novel (i.e., not unnecessarily duplicative of other
published work.) If alternative methods or procedures representing refinements to your procedures
were found, please discuss why those alternatives cannot be used:
No alternatives to animal-based nerve regeneration studies was identified. This proposed procedure does not
duplicate any current or previously published work.
Because of our experience in the previous studies with this topic we were able to reduce the total number of
animals 50% (n=270).
Because of our results from this study during the last 3 years there is no need to repeat the same amount of
experiments. We think if we combine the new with our previous results we are still able to get significant data. So we
reduced the number of needed animals in the current protocol 50%. We did not change any procedures and techniques.

SECTION 3: EXPERIMENTAL DESIGN

Provide a concise description of the experimental design below, describing all experiments to be
performed. For each experiment, provide the following information:
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1. Briefly describe the rationale behind the experiment or the hypothesis being tested (i.e., the
reason for performing the procedure).
2. Define the groups and number of animals per group needed for the experiment, including both
experimental and control animals, and list the procedures to be performed on each group. A
table or block design may be an effective way to present this information.
3. Explain how the number of animals for the experiment was determined to be adequate for the
generation of statistically significant data (i.e., power analysis, previous publications).
4. Describe the sequence and timing of all live animal procedures to be performed, according to the
groups defined in #2 above. Provide a timeline, diagram or flowchart if appropriate.
5. Define the procedural endpoints for each group of animals defined in #2 above (i.e., what
determines when the live animal portion of the experiment is complete and animals are
euthanized.)
Notes:
x Do not cut and paste from a grant application, journal article or abstract.
x Do not provide a detailed description of the procedures here. These details should be provided in
Sections 5 and 6 of the protocol narrative.
x Do not provide detailed descriptions of analytical methods or procedures that do not involve the
use of animals.

HEK-293 cells are ubiquitous and easily transfected. The HEK-293 cells offer advantages over our previous
fibroblast cell line in that the HEK-293 cells are 1) Commercially available, 2) Easily transfected, 3) Well
studied, 4) Virtually no cellular output (i.e collagen). Although we have been able to transfect HEK-293 cells
with NGF and have demonstrated inducible NGF secretion and its biological activity, questions regarding
potential alterations to cellular function remain. It is the purpose of this Specific Aim to answer these questions
and complete our evaluation of the regulatory system.
Specific Aim #1:

No animals used. HEK-293 cell culturing, sorting and preparing for transfection.

Specific Aim #2:
No animals used. Transfection of the cells with our NGF- and HSV-TK-codons and
preparation for the conduits.
Specific Aim #3:
The following groups will be utilized:

Group 1
(N=10)

hNGF-EcR-293 induced Pon (+) [via infusion catheter]

Group 2
(N=10)

hNGF-EcR-293 induced Pon (+) [intraveneously]

Group 3
(N=10)

hNGF-EcR-293 noninduced Pon (-)

Group 4
(N=10)

HEK-293 nontransfected cells Pon (+) [via infusion catheter]
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Group 5
(N=10)

HEK-293 nontransfected cells Pon (+) [intraveneously]

Group 6
(N=10)

HEK-293 nontransfected cells Pon (-)

Group 7
(N=10)

Empty PLLA conduit

Group 8
(N=10)

PLLA conduit filled with Vitrogen

Group 9
(N=10)

hNGF-EcR-293 (TK+) induced with Pon (+) and treated with Ganciclovir (+) [via infusion catheter]

Group 10
(N=10)

hNGF-EcR-293 (TK+) induced with Pon (+) and treated with Ganciclovir (+) [intraveneously]

Group 11
(N=10)

hNGF-EcR-293 (TK+) noninduced with Pon (-) and treated with Ganciclovir (-)

Group 12
(N=10)

Cultured Schwann cells

Group 13
(N=15)

Isograft controls from 5 donor animals

270 nude rats will be utilized within this study in a multi-modal analysis to test the variables. The use of nude
rats precludes potential immunologic reactions with the human NGF or HEK-293 cells. The cells suspended in
media as outlined above for each group will be placed within PLLA conduits bridging a 10 mm nerve gap in the
sciatic nerve. Cell concentration will be 1000 cells in the conduits after administration as determined from
previous studies and the minimum amount of Ponasterone A will be determined from SA 1. We know from our
preliminary data that further administration of Ponasteron A at later time points will improve the outcome.
Therefore all groups but Group 5 and Group 10 will be locally reboostered with Ponasteron A at day 3, 5,
10,and 14 via a catheter placed directly at the conduit. The purpose of noninducible hNGF-EcR-293 cells are to
determine the effect on nerve regeneration of potential secretory proteins produced by these cells alone.
Additional control groups with empty PLLA conduits, conduits filled with collagen and isografts will be
employed. In the control group with isografts from 5 donor animals the sciatic nerve of the right and the left leg
of the donor animals will be harvested and surgically implanted in the right sciatic nerve of 10 control animals
as a nerve graft. Alltogether for this group, 15 animals will be needed. In addition to the stimulatory animals,
hNGF-EcR-293 cells transfected with a herpes simplex virus-thymidine kinase gene (HSV-TK) will be treated
by Ganciclovir and placed at 1000 cells per conduits in additional animals. A final group of transfected but
nontreated with Ganciclovir will be conducted. All cells will be placed within the PLLA conduits at the time of
surgical intervention. The PLLA conduits will be harvested at days 3,5,10,14, and 21. The primary endpoint of
this SA will be the NGF production by our cell line and will be determined by protein analysis using ELISA
and immunohistochemistry and its gene expression using RT-PCR. The secondary endpoints are the expression
of Gap-43, actin, myosin II, tubulin, fibronectin, laminin, trk A, B, C and p75. These variables will also be
analyzed by ELISA, RT-PCR and immunohistochemistry to determine the extent of up or down regulation
based on the delivery of NGF. The overall number of animals used for this SA is justified by the fact that this
study is based upon preliminary studies and the need to obtain a minimum number of animals per group (n=10)
to test the hypothesis as determined by statistical power analysis. To achieve a statistical power of 85% in our
setting the minimum number to treat is n=19.
Specific Aim #4:
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This SA will be conducted with 135 nude rats. Administration of Ponasterone-A dosing will be determined
from SA 1. The animals will have the 15 mm PLLA conduits placed into a sciatic nerve defect in the right leg
as outlined in SA 3 and the groups will include:
Group 1
(N=15)

Isograft controls from 5 donor animals

Group 2
(N=10)

hNGF-EcR-293 induced with Pon (+) [via infusion catheter]

Group 3
(N=10)

hNGF-EcR-293 induced with Pon (+) [intraveneously]

Group 4
(N=10)

hNGF-EcR-293 noninduced with Pon (-)

Group 5
(N=10)

HEK-293 nontransfected cells Pon (+) [via infusion catheter]

Group 6
(N=10)

HEK-293 nontransfected cells Pon (+) [intraveneously]

Group 7
(N=10)

HEK-293 nontransfected cells Pon (-)

Group 8
(N=10)

Empty PLLA conduit

Group 9
(N=10)

PLLA Conduit filled with Vitrogen

Group 10
(N=10)

hNGF-EcR-293 (TK+) induced with Pon (+) and treated with Ganciclovir (+) [via infusion catheter]

Group 11
(N=10)

hNGF-EcR-293 (TK+) induced with Pon (+) and treated with Ganciclovir (+) [intraveneously]

Group 12
(N=10)

hNGF-EcR-293 (TK+) noninduced with Pon (-) and treated with Ganciclovir (-)

Group 13
(N=10)

Cultured Schwann cells

Functional analysis will be conducted monthly through 4 months. This will be performed by walking track
analysis as outlined below and will used as the primary endpoint. This analysis serves as an indirect measure
of nerve reinnervation. At the end of 2 and 4 months, direct nerve to nerve stimulation will be performed on
the sciatic nerve to assess conduction velocity and peak electrical amplitude. The gastrocnemius muscle will
be harvested and weighed in order to assess nerve reinnervation following nerve stimulation. The
gastrocnemius muscle is supplied by the posterior tibial branch of the sciatic nerve. Once the nerve is severed,
the muscle will begin to atrophy. As the nerve regenerates into the muscle, it will regain its mass proportional
to the amount of reinnervation. This will provide indirect measurements of nerve regeneration. Comparisons
of the percentage will be performed between groups in order to potentially avoid normal differences in muscle
weight between individual animals. By using this indirect technique for proportional measurements we will be
able to save a complete group of animals. When muscle weight is compared between groups using absolute
values instead of proportional changes another control group would first have to determine normal values of
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the gastrocnemius muscle in these rats. In addition, the distal nerve and conduit/isografts will be harvested and
histomorphologic analysis performed. The null hypothesis for statistical analysis in this SA is that there will
be no significant difference between the functional parameters for the control isografts and the experimental
groups. The secondary endpoints of this SA are changes in muscle weight and the histomorphological analysis
of the distal nerve, conduit and isograft.
After 2 moths the first half of the animals will be conducted to terminal surgery for electrical nerve
analysis and following muscle harvest. After 4 months the second half will be assessed and
muscles will be harvested.

(135 for SA 3 and 135 for SA4; Group 13 in SA 3 and Group 1 in SA 4 will need 15 animals each [5 donor
animals and 10 reciepient animals])

SECTION 4: ANIMAL REQUIREMENTS AND USDA PAIN CATEGORIES
Based upon the design above, provide the following information about the animals in this project:
x Genus-Species or Common Name: list the genus-species or common names of all vertebrate
animals involved in the experimental design.
x Strain: List separately any special strains. Each animal should be accounted for once in the table.
x Condition Code: Assign a condition code for each species. These codes are used for animal
purchase, transfer and reporting of animals numbers.
x USDA pain category: Assign a USDA pain/distress category for each species.
x Total # required: Indicate the total number of animals involved in the project for the duration of
the project or 3 years, whichever is less.
SPECIES
STRAIN
CONDITION
USDA PAIN
TOTAL #
CODE
CATEGORY
REQUIRED
(B, C, D, or E*)
Rat
Nude
Mature
D
270
Rat

Sprauge Dowley

Mature

D

20

*Animals in Category E: Unrelieved pain, distress or discomfort requires strong scientific justification
with particular attention to the significance, necessity, and potential benefits of the research.
x Investigators must perform euthanasia on all moribund experimental animals unless there is
scientific justification that euthanasia would invalidate experimental data collection.
x If euthanizing a moribund animal would seriously harm the study, the scientific justification for
using death as an endpoint must be provided below.
x Click here for additional information about UCI’s euthanasia policy and alternative endpoints.
Scientific Justification for Animals in Category E: Type here

SECTION 5: DESCRIPTION OF NON-SURGICAL PROCEDURES

Describe in detail all non-surgical procedures to be performed on live animals.
x Indicate with an “X” in the bracket [ ] if non-surgical procedures will not be performed in live
animals.
x Procedures described here must be referenced in Section 3.
x Animal monitoring and management (as applicable) must be addressed in Section 7.
x Each subsection below should be completed as it applies to the protocol.
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x
x
x

[

A ULAR veterinarian should be consulted in the planning of non-surgical procedures involving
potential pain and/or distress.
Click on “Section 5” above for detailed instructions.
If a procedure does not apply state “N/A”.

] Not applicable – Non-surgical procedures will not be performed on live animals. Skip the rest of
this section.

1. Euthanasia followed by Tissue Harvest:
Harvest of conduits and nerves:
Tissue harvest will only occur during the terminal surgical procedure. Site of sciatic nerve defect and conduit
implantation will be harvested at defined time points.
Gastrocnemius mascle harvest and weight:
Both the medial and lateral gastrocnemius muscle will be harvested. Muscle will be placed in preweighed sterile
saline containers so that desiccation does not occur. The difference in weight of the containers before and after
muscle placement will determine the muscle weight. Weights of the injured (experimental) and noninjured
(control) leg will be compared to determine a percentage.
2. Blood and Tissue Collection in Live Animals:
N/A
3. Behavioral Studies:
Nerve regeneration functional analysis:
Walking track analysis (sciatic functional index - SFI) will be performed monthly through 2-4 months.
Preoperatively, the animals are trained to walk down a 30 x 4 inch track into a darkened enclosure.
Postoperatively, the rats’ hind paws are painted with water soluble ink and any changes in their paw prints
caused by nerve injury and denervation will be recorded. Three different parameters of the rodents paw
print are measured to determine the sciatic functional index. This number is traditionally expressed as a
negative. Values tending toward zero indicate improved functional recovery:
Sciatic Functional Index = -38.3 (PLF) + 109.5(TSF) + 13.3 (ITF) - 8.8
PLF = Print Length Function = (Experimental PL - Normal PL)/Normal PL
TSF = Toe Spread Function = (Experimental TS - Normal TS)/Normal TS (1st to 5th Toe)
ITF = Intermedian Toe Spread Function = (Experimental IT-Normal IT)/Normal IT (2nd - 4th Toe)
4. Administration of Experimental Agents:

Ponasterone A is the agent, that when administered, will induce the transfected 293 cells to secrete NGF. To
determine the optimal route of delivery of Ponasterone A will be administered through an infusion catheter
[IC] or intravenously [IV] in the specified groups at day 3, 5, 10 and 14. Ganciclovir will only be administered
locally at the time of surgery.
AGENT
PURPOSE
PonA
(inducing agent)
PonA

DOSE (mg/kg body weight)

ROUTE

FREQUENCY

3 mL of 3 uM

intracathete

x4 administration

3 mL of 3 uM

intravenous

x4 administration
UCI INSTITUTIONAL ANIMAL CARE & USE COMMITTEE

Page 14 of 22
___________________________________________________________________________________________________________________________
IACUC #: 2000-2192-3
Mod #: 2
Approved by IACUC on: 01-13-11
Void After: 01-05-13
(IACUC USE ONLY - DO NOT ALTER THIS FOOTER)

(inducing agent)
Ganciclovir
(turn-off NGF)

150 mg/Kg

local

once

The catheter connected to the conduit will be placed during the first surgery. For iv administration we will use the femoral
vein. We will clarify with the campus veterinarians if the volume of 3ml slowly injected is to high or not. We are open to
adjust the volume for an optimal administration.
We consulted Dr. Roger Geertsema regarding the administration of 3ml volume iv. For a 400500g rat, which we will use, 3ml volume for iv-administration is possible, but the upper limit.

5. Induction of Anesthesia/Sedation for Non-surgical Procedures:
x

Indicate how anesthesia/sedation is induced:

x

Describe how the level of anesthesia/sedation is assessed to be adequate to begin the
procedure:

x

Describe how animals are monitored (e.g., respiration pattern, response to noxious stimulation
(e.g., paw pinch), heart rate/pattern, EKG, blood pressure, temperature, etc.) throughout the
procedure and discuss any supplemental anesthesia dosing required:

x

If animals will be placed on artificial ventilation, describe the range of respiration rates and tidal
volumes.

x

For survival procedures, describe how animals are monitored for recovery from
anesthesia/sedation and when animals are returned to their home cages. Estimate how long it
will take for the animal to recover from anesthesia/sedation (i.e., ambulatory and feeding).

6. Imaging Procedures:
Histomorphometric analysis:
The distal nerve will be harvested, fixed with 3% glutaraldehyde, embedded in epoxy resin, sectioned and
stained with toluidine blue. Histomorphometric analysis will be performed by histology coupled with
digital image processing and analysis. Briefly, nerve conduit sections stained with toluidine blue will be
placed on the stage of an inverted microscope and viewed with bright field optics. Images of the
histological sections will be digitized using a CCD camera and subsequently analyzed using standard and
sophisticated image processing techniques. Images will be thresholded and segmented into individual axons.
The number of axons per three randomly selected regions measuring 80 x 60 microns will be counted to
give the number of axons/mm2. The area of each axon will be determined, summed, and expressed as
axons/image area to give the nerve fiber density.

7. Cardiac Perfusion:
N/A
8. Other Non-surgical Procedures:
Conduit fabrication:
Poly(L-lactic acid) (PLLA) (Birmingham Polymers, Birmingham, AL) will be manufactured into porous
biodegradable conduits using a combined solvent casting, extrusion, and particulate leaching technique.
The PLLA conduits will be IDEULFDWHGZLWKDSRURVLW\RIDSRUHVL]HEHWZHHQDQGȝ0DQGDQ
extrusion temperature of 275°C. The resultant conduits will have an inner diameter of 1.6 mm, an outer
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diameter of 3.2 mm, and a length of 15 mm. This portion of the proposals SAs will involve the assistance
of consultant Charles Patrick, Jr. Ph.D. Previous studies with our transfected hDFBs have indicated
degradation of the PLLA conduit does not cause cell death.
Protein Analysis:
To assess that the NGF protein is secreted in vivo, conduits will be harvested at 3, 5, 10, 14 and 21 days
and fluid within the conduit will be aspirated with the help of a 30 gauge tuberculin syringe (Ethicon).
Analysis for NGF production by ELISA using Emax NGF-ELISA kit (Promega) as per the manufacturer’s
protocol will be conducted. Protein expressions will also be assesed of Gap-43, actin, myosin II, tubulin,
fibronectin, laminin, trk A, B, C and p75.
RT-PCR and Immunohistochemistry in tissue:
To characterize axonal/support cell interaction upon NGF production, RNA harvested from these conduits
will be used to asses the status of Gap-43, actin, myosin II, tubulin, fibronectin, laminin, trk A, B, C, NGF
expression and p75 by RT-PCR using primers specific to respective genes. Protein expression levels of
these genes within the conduit will also be assessed by immunohistochemistry. The nerve conduits will be
fixed, embedded and sectioned (5 micron) (see E.3.3.4). These sections will be used for
immunohistochemical analysis of above mentioned support cell genes using labeled antibodies specific to
respective proteins.
Electrical conduction studies:
At the end of 2 and 4 months, direct nerve to nerve stimulation will be performed on the sciatic nerve to
assess conduction velocity and peak electrical amplitude. After deep intramuscular anesthesia as outlined
above, ½ of the animals randomly selected in each subdivided group will be placed on a Harvard ventilator
(New England Medical Instruments #122, Medway MA) delivering 300 ml of 100% O2 per minute through
oral tracheal intubation with a 14 gauge angiocatheter (Terumo Medical Corp, Elkton, MD).
Electrophysiologic testing will then be performed using an Advantage 3000 Series (London, Ontario
Canada) nerve stimulator. At the conclusion of the electrical conduction studies, the medial and lateral
gastrocnemius muscle will be harvested and weighed in order to assess nerve reinnervation as outlined
above.

9. Post-procedural Care (as applicable):
N/A

SECTION 6: SURGICAL PROCEDURES
Describe in detail all surgical procedures to be performed.
x Indicate with an “X” in the bracket [ ] if surgical procedures will not be performed on live animals.
x Any procedures described here must be referenced in Section 3.
x Animal monitoring and management (as applicable) must be addressed in Section 7.
x Each subsection below should be addressed as it applies to the surgical procedure.
x Address each of the applicable subparts for each surgery to be performed.
x Click on “Section 6” above for detailed instructions.
x If a procedure does not apply, state “N/A”.

[

] Not applicable – Surgical procedures will not be performed on live animals.
Skip the rest of this section.
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A. Pre-operative Care:
Food and water will be provided ad libitum
B. Induction of Anesthesia for Surgical Procedures:
x

Indicate how anesthesia is induced:
General anesthesia will be induced and maintained by a 0.4 ml intramuscular injection of a premixed
solution containing 95 mg/kg ketamine HCL (Keta-StheticTM, Boehringer Ingelheim, St. Joseph, MO),
6 mg/kg xylazine (RompunTM, Miles, Shawnee Mission, KS), and 0.05 mg/kg atropine sulfate (ElkinsSinn, Cherry Hill, NJ). If needed a supplemental dose of 0.1ml of the premixed solution will be given.

x

Describe how the level of anesthesia is assessed to be adequate to begin the procedure:

x

Describe how animals are monitored (e.g., respiration pattern, response to noxious stimulation
(e.g., paw pinch), heart rate/pattern, EKG, blood pressure, temperature, etc.) throughout the
procedure and discuss any supplemental anesthesia dosing required:
Depth of anesthesia will be assessed intra-operatively by changes in muscle tone and, by changes in
respiratory rate. Changes in muscle tone provides an earlier warning to changes in depth of anesthesia
than toe-pinch. Changes in muscle flaccidity and/or changes in respiratory rate will indicate the need to
adjust delivery of anesthetic.

x

If animals will be placed on artificial ventilation, describe the range of respiration rates and tidal
volumes.
N/A

x

For survival procedures, describe how animals are monitored for recovery from anesthesia and
when animals are returned to their home cages. Estimate how long it will take for the animal to
recover from anesthesia (i.e., ambulatory and feeding).

At the conclusion of surgery, buprenorphine will be given subcutaneously and bacitracin will be applied
topically to the suture site. Animals will be monitored until ambulatory (2-4 hours after surgery) and before
returning them to their home cages. Food and water will be given from the return on to their home cages.
C. Aseptic Techniques:
x

Preparation of the surgical space:
Topical sterilization with 70% ethanol

x

Preparation of the surgeon(s):
Standard surgical hand scrub and sterile gowning with masks, hats.

x

Preparation of the animal(s):
Topical betadine solution

x

Sterilization of instruments:
Autoclave
UCI INSTITUTIONAL ANIMAL CARE & USE COMMITTEE
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D. Surgical Procedure:
Surgical technique: Cells as outlined in the above groups will be seeded within the PLLA conduits with a
seeding density of 103 suspended in Vitrogen and implanted into a surgically created nerve defect in the sciatic
nerve of nude rats. Briefly, the right lower extremity of the animal will be shaved and prepared in an antiseptic
fashion with betadine (AMSCO Medical Products, PA). The sciatic nerve will be exposed by a muscle splitting
incision. The PLLA conduits, sterilized with ethylene oxide, will be placed into this sciatic nerve defect with 1
mm of the proximal and distal nerve ends invaginating into the conduit. Conduits will be sutured to the nerve
using 10-0 nylon (Sharp Point) suture and microsurgical technique. One end of the nerve will be sutured within
the conduit. Application of the cell suspended in Vitrogen will then be applied with a 27G needle (Becton
Dickinson). Once this is completed, the other end of the nerve will be sutured in place allowing a “cap” to the
filled conduit. This technique has worked for us in the past. One end of an infusion catheter will be connected to
a conduit that will be interposed between the ends of a sciatic nerve defect. The injection port end will be placed
on the dorsum subcutaneously. Ponasterone will be injected through the injection port at day 3, 5, 10, and 14 for
all groups but Group 5 and Group 10. This will allow delivery of the agent to the conduit. In separate animals,
Ponasterone A will be adiministered intravenously. The muscle of the leg will be closed using 4-0 Dexon sutures
(Davis+Geck, Wayne, NJ) and skin staples used for wound approximation (Stoelting, Wood Dale, IL). At
3,5,10,14 and 21 days following conduit placement, 4 randomly selected animals at each time point for each
group (total 10 per group) will again be anesthetized with the above intramuscular medications. Cells and
contents within the PLLA conduit will be collected. In addition, sections of the distal nerve will be harvested for
histomorphology. Staining and evaluation will proceed as outlined above.
Note: Animals in which a sciatic nerve defect will be created will undergo two surgical procedures:
During the 1st surgical procedure a sciatic nerve defect will be created and the PLLA conduit implanted
[interposed over the ends of the sciatic nerve]. During the 2nd surgical procedure, the PLLA conduit will be
harvested following direct nerve to nerve stimulation. This 2nd surgical procedure will be a terminal procedure.
E. Methods to Prevent Dehydration & Hypothermia:
Lactated Ringers or normal Saline will be given subcutaneously to prevent dehydration. A heating pad will be
used to minimize hypothermia.
F. Surgical Endpoints and Post-operative Care:
Survival surgery will conclude with the closure of the skin incision [approximately 15 minutes following the
iniating skin incision]. Terminal surgery will conclude with administration of an overdose of pentobarbital that
will be given at the conclusion.
At the conclusion of surgery, buprenorphine will be given subcutaneously and bacitracin will be applied
topically to the suture site. Animals will be monitored until ambulatory and before returning them to their home
cages. Each animal will be monitored daily including weekends. Animals will be assessed for pain, distress and
discomfort during daily monitoring.
Animals will be monitored daily during the 1st five post-operative days and buprenorphine and/or
carprofen administered for pain management. The first dose of buprenorphine will be adminisered to the
animals as they begin to recover from the procedural anesthetics. Injections of buprenorphine will be
administered to each animal for the first 24 hours (q 8 to 12 hours) and on a PRN basis thereafter. After
24 hours the animals get Carprofen daily (q 12 to 24 hours) for 5 days, then as needed.

SECTION 7: ADVERSE EFFECTS & ANIMAL MONITORING AND MANAGEMENT
Please answer each of the questions below. Note: A “not applicable” answer applies only to
experiments in which naive animals will be euthanized for harvest of tissue only, without prior
experimental intervention.
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A. Briefly summarize all possible adverse effects or phenotypic abnormalities that may present in the
animals as a result of study procedures, agents, disease processes, genetic alterations, etc.
(Example: tumor formation, ascites, neurologic deficits, moribundity, etc.)

See section B.

B. Describe the clinical signs and symptoms that may appear in the animals as a result of the
experimental procedures or agents, including any associated pain, distress or discomfort.

Unrestricted weight-bearing activity will be allowed as tolerated postoperatively. Autonomy of the denervated
foot can follow sciatic nerve resection resulting in walking impairment. Painting the foot with substances which
are not harmful, such as cayenne pepper extract, quinine solution, or Biter Apple can assist in the prevention of
this behavior.

C. Describe the monitoring parameters (i.e., signs, symptoms and species-specific behaviors) that
will be used to assess pain, distress and discomfort in animals.

Retraction from observer, huddled in a fetal position, ruffled hair coat and excessive weightloss are warning
sings for pain, stress and discomfort and should not have been detected during daily observation.

D. Describe the management plan that will be used to assess and treat pain, distress and discomfort
in the animals, including any special procedures that will be used (e.g., periodic weighing of
animals) and any interventions that will be performed to relieve pain, distress and discomfort in the
animals (e.g., analgesics, antibiotics, special housing/bedding, etc.)

Animals will be monitored daily during the 1st five post-operative days and buprenorphine and/or carprofen
administered for pain management. The first dose of buprenorphine will be adminisered to the animals as they
begin to recover from the procedural anesthetics. Injections of buprenorphine will be administered to each
animal for the first 24 hours (q 8 to 12 hours) and on a PRN basis thereafter. After 24 hours the animals get
Carprofen daily (q 12 to 24 hours) for 5 days, then as needed.
Note: Analgesia will be administered during the first 5 post-operative days. Animals will be assessed for pain,
distress and discomfort during daily monitoring and the Campus Veterinarian consulted if evidence of pain
becomes apparent.
Every animal with a sciatic nerve defect will be observed daily, including weekends. If it can be predicted that
an animal will mutilate it’s foot within 24 hours, that animal will be euthanized immediately. Any animal
presenting any evidence of foot mutilation will immediately be euthanized.
E. Indicate the frequency in which animals will be monitored to assess their well being.

Animals will be assessed for pain, distress and discomfort during daily monitoring.
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F. Describe how the monitoring of animals (e.g., daily observations and treatments performed by
research staff) will be documented. Monitoring records should be kept in the animal room and
must be readily available to ULAR veterinary staff and IACUC members at all times.
Routine monitoring will be recorded with an animal protocol and indications on the cage cards.

G. Describe the criteria that will be used to determine that an animal must be removed from the study
ahead of schedule and euthanized. (Click here for euthanasia criteria.)

Animals will be assessed for pain, distress and discomfort during daily monitoring. Any animal exhibiting
unalleviated pain or distress [retraction from observer, huddled in a fetal position, ruffled hair coat] will be
euthanized immediately.

SECTION 8: EXPERIMENTAL AGENTS AND THERAPEUTIC DRUGS
A. Table of Drugs/Agents Used in Live Animals
List all anesthetic, therapeutic drugs and experimental/study agents administered to live animals.
x Drug/Agent: list the name of the drugs or agents used in this project.
o Experimental agents include placebos, viruses and other biological agents, tumor cells,
gene markers, tracers, radioisotopes, etc.
o Therapeutic drugs include anesthetics, analgesics, tranquilizers, antibiotics, fluids and
other agents such as antimicrobials and paralytics.
o Do not list euthanasia drugs in this section. Agents used to euthanize animals,
including anesthetic overdoses, should be identified in Section 9.
o Note: Rodent biological materials, including cell lines, may require testing for pathogens
prior to use.
x Controlled Substances: Indicate with an “X” in the bracket [ ] if the drug is on the U.S. Drug
Enforcement Agency’s list of Controlled Substances
x Purpose: Use the following codes for the purpose column--Pre-anesthetic (PA); Anesthetic (A);
Therapeutic (T); Experimental (E).
x Dose Range: Express dosages as a range and as mg/kg of body mass, wherever possible.
x Route: Use the following codes for routes of administration—intravenous (IV); intramuscular (IM);
subcutaneous (SC); intraperitoneal (IP); per os –by mouth (PO); by inhalation (Inhl)
x Frequency: Specify how often the drug/agent will be administered in each animal in a 24 hour
period
x Period of Administration: Specify how long the drug/agent will be used in each animal while it is
in the study.
Note: Use the “Tab” key to create additional rows in a table by placing your cursor in the last cell of
the table.
Species

Rat

Drug/Agent

Contr’d
Subs?

Ketamine
Xylazine
Atropnie
Buprenorphine

[X]
[X]
[ ]
[X]

Purpose

Anesthesia
Anesthesia
Anesthesia
Analgesia

Dose Range

95mg/kg
6mg/kg
0.05mg/kg
0.01 to 0.05
mg/kg

Route

IM
IM
IM
SC

Frequency

Period of
Admin

Once
Once
Once
Q 8 to 12 hrs
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Cayenne
pepper extract
Bitter apple

[ ]

Quinine

[ ]

Ponasterone A

[ ]

Prevent foot
mutilation
Prevent foot
mutilation
Prevent foot
mutilation
NGF
production
Stop NGF
production
Wound
protection
Desinfection
Cell carier
NGF
production
Analgesia

[ ]

Ganciclovir
Bacitractin
Betadine
Vitrogen

hNGF-EcR293 cells
Carprofen

Smear

Topical

As needed

Smear

Topical

As needed

Smear

Topical

As needed

2 uM/kg

Intra conduit

As needed

10 uM/kg

Intra conduit

Once

Smear

Topical

Once

Liquid
Gel/liquid
Cells

Topical
Intraconduit
Intracoduit

Once
Once
Once

4-5mg sc or
0.04mg/ml
water po

Sc or po

Q 12-24 hrs

SECTION 9: EUTHANASIA METHODS
A. Place an “X” in the bracket [ ] next to the method(s) of euthanasia to be used.

[ X ] Anesthetic Overdose (complete the table below)
SPECIES

Rat

[

AGENT

Eutha-6

DOSE

150-200mg/kg animal
body weight

ROUTE OF
ADMINISTRATION
IV

] Physical Method
[

] Decapitation (describe):

Type here
[

] Cervical Dislocation (describe):

Type here
[

] Cardiac Perfusion: (describe):

Type here
[

] Other (describe):

Type here

B. Indicate how death of the animals will be confirmed:
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[ X ] Direct (open chest) inspection of the heart
[

] Decapitation

[

] Exsanguination

[

] Other (describe): Type here

SECTION 10: ROLES, RESPONSIBILITIES AND EXPERTISE OF THE STUDY TEAM

List below all study team members who will have contact with live animals.
1.
2.
3.
4.

Describe each person’s specific role and responsibility on the project, including the
procedures they will perform.
Indicate who will be responsible for the daily care and monitoring of the animals.
Provide a description of their qualifications, level of training and expertise.
If a study team member does not have relevant experience or training for a particular species or
procedure they will perform, describe how they will be trained.

Lead Researcher:
Dr. Gregory Evans: Head of division and the PI on this project. Dr. Evans will oversee the project desing,
procedure, and completion. He will conduct surgical teaching to the additional personnel through observation.
Dr. Evans will be active in all surgical procedures. He has 5 years of general surgery training, 6 years of plastic
surgery training, 1 year of microsurgery training, and over 15 years experience with rodent-based protocols.

Co-Researcher(s):
Garret Wirth, M.D.: Over 10 years of general and plastic surgery training. He will conduct surgical teaching
to the additional personnel through observation. Dr. Wirth will be active in all surgical procedures.
Dr. Thomas Scholz: Will be involved in all surgical procedures as well as post-harvest processing and assays.
He will be involved in the pre-intra- and post-operative care of the animals. He has 3 years general surgery
training, and over 6 years of animal-based protocol experience including rats and pigs. Primarily responsible for
conducting the behavioral studies.
Research Personnel:
Donald Mowlds: Medical student, available for assiting in Lab work and animal care.
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Vita
Mireya Aidee Perez is a native of El Paso, TX and a 2003 graduate from Coronado High School.
After that, she obtained a Bachelor of Science in Biological Sciences with a minor in Chemistry from
the University of Texas at El Paso (UTEP) in May of 2007. During her undergraduate career, she was
an active member of the Medical Professions Organization. As a member, she participated in various
community service projects, including working as a volunteer at University Medical Center. She also
conducted research at the Analytical Core Cytology Facility, directed by Dr. Joanne T. Ellzey. For two
years, she was employed by Alternative Personal Care as Human Resources Coordinator and Staff
Trainer. She decided to continue her education by re-enrolling at UTEP and pursuing a Master of
Science in Biomedical Engineering. During her graduate studies, she participated in the Texas TechUTEP Collaborative Clinical Shadowing Program, enriching her exposure to the medical field. She was
also employed as a graduate research assistant at the W.M. Keck Center for 3D Innovation, directed by
Dr. Ryan B. Wicker, where she conducted research focused on the biomedical applications of additive
manufacturing. Her research has been presented at international conferences such as the Solid Freeform
Fabrication Symposium and the Biomedical Engineering Society’s Annual Meeting.

Permanent address:

4445 Lazy Willow Dr.
El Paso, TX, 79922

This thesis was typed by Mireya Perez.
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